Menu

Wolfson Institute of Preventive Medicine

Search - ZOO
Search - K2
Search - Categories
Search - Contacts
Search - Content
Search - Newsfeeds
Search - Weblinks

Publications

We maintain an archive of past and current publications which can be searched by clicking on the links to the left or by using the drop down menus at the top of this page to search by author name, journal name or year of publication.

Alternatively you can use the search bar to look up a key word.

Our most recent publications are listed below.

Jack Cuzick Publications

Authors

Publication Summary

Journal

Years

Cuzick J, Myers O, Lee J-H, Shi Y, Gage JC, Hunt WC, Robertson M, Wheeler CM, New Mexico HPV Pap Registry Steering Committee Outcomes in Women With Cytology Showing Atypical Squamous Cells of Undetermined Significance With vs Without Human Papillomavirus Testing.. vol.3, (10) 1327 - 1334.
10.1001/jamaoncol.2017.1040
JAMA Oncol2017
Lorincz AT, Nathan M, Reuter C, Warman R, THAHA MA, Sheaff M, Vasiljevic N, Ahmad A, CUZICK JM, Sasieni P Methylation of HPV and a tumor suppressor gene reveals anal cancer and precursor lesions. vol.8, (31) 50510 - 50520.
10.18632/oncotarget.17984
Oncotarget2017
Curigliano G, Burstein H, Winer E, Gnant M, Dubsky P, Loibl S, Colleoni M, Regan M, Piccart-Gebhart M, Senn H, Thurlimann B De-escalating and Escalating Treatments for Early Stage Breast Cancer: The St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017. vol.28, (8) 1700 - 1712.
10.1093/annonc/mdx308
Annals of Oncology2017
CUZICK JM Preventive Therapy for Cancer. vol., () .
10.1016/S1470-2045(17)30536-3
Lancet Oncology, The2017
Thorat MA, Cuzick J Preventing invasive breast cancer using endocrine therapy.. vol., () .
10.1016/j.breast.2017.06.027
Breast2017
Bartlett JMS, Ahmed I, Regan MM, Sestak I, Mallon EA, Dell'Orto P, Thürlimann B, Seynaeve C, Putter H, Van de Velde CJH, Brookes CL, Forbes JF, Viale G, Cuzick J, Dowsett M, Rea DW, Translational Aromatase Inhibitor Overview Group (Trans-AIOG) HER2 status predicts for upfront AI benefit: A TRANS-AIOG meta-analysis of 12,129 patients from ATAC, BIG 1-98 and TEAM with centrally determined HER2.. vol.79, () 129 - 138.
10.1016/j.ejca.2017.03.033
Eur J Cancer2017
Smith SG, Sestak I, Howell A, Forbes J, Cuzick J Participant-reported symptoms and their impact on long-term adherence in the International Breast Cancer Intervention Study (IBIS-1). vol.35, (23) .
10.1200/JCO.2016.71.7439
Journal of Clinical Oncology2017
Benard VB, Castle PE, Jenison SA, Hunt WC, Kim JJ, Cuzick J, Lee J-H, Du R, Robertson M, Norville S, Wheeler CM, New Mexico HPV Pap Registry Steering Committee Population-Based Incidence Rates of Cervical Intraepithelial Neoplasia in the Human Papillomavirus Vaccine Era.. vol.3, (6) 833 - 837.
10.1001/jamaoncol.2016.3609
JAMA Oncol2017
Taylor C, Correa C, Duane FK, Aznar MC, Anderson SJ, Bergh J, Dodwell D, Ewertz M, Gray R, Jagsi R, Pierce L, Pritchard KI, Swain S, Wang Z, Wang Y, Whelan T, Peto R, McGale P Estimating the Risks of Breast Cancer Radiotherapy: Evidence From Modern Radiation Doses to the Lungs and Heart and From Previous Randomized Trials. vol.35, (15) 1641 - 1649.
10.1200/JCO.2016.72.0722
Journal of Clinical Oncology2017
CUZICK JM, Bartlett J, Ikhlaaq A, Regan MM, Sestak I, Mallon EA, Dell'Orto P, Thürlimannh B, Seynaevei C, Putter H, Van de Velde C, Brookes CL, Forbes JF, Viale G, Dowsett M, Rea D HER2 status predicts for upfront AI benefit: a TRANS-AIOG meta-analysis of 12129 patients from ATAC, BIG 1-98 and TEAM with centrally determined HER2. vol., () .
10.1016/j.ejca.2017.03.033
European Journal of Cancer2017
CUZICK JM, Smith SG General practitioner attitudes towards prescribing aspirin to carriers of Lynch Syndrome: findings from a national survey. vol., () .
10.1007/s10689-017-9986-9
Familial Cancer2017
Ussi AE, Rebolj M, Thorat MA, Bietrix F, Fauvel A-C, Hajdúch M, Hill C, Walker I, van Engeland M, Cuzick J, Meijer G Assessing opportunities for coordinated R&D in early cancer detection and management in Europe.. vol.140, (7) 1700 - 1701.
10.1002/ijc.30564
Int J Cancer2017
CUZICK JM, Cadman L, Ahmad AS, Ho L, Terry G, Kleeman M, Lyons D, Austin J, Stoler MH, Vibat C, Dockter J, Robbins D, Billings P, Erlander MG Performance and Diagnostic Accuracy of a Urine-Based Human Papillomavirus Assay in a Referral Population. vol., () .
10.1158/1055-9965.EPI-16-0960
Cancer Epidemiology, Biomarkers and Prevention2017
Sestak I, Buus R, Cuzick J, Dubsky P, Kronenwett R, Ferree S, Sgroi D, Schnabel C, Baehner R, Mallon E, Dowsett M Comprehensive comparison of prognostic signatures for breast cancer in TransATAC. vol.77, () .
10.1158/1538-7445.SABCS16-S6-05
CANCER RESEARCH2017
Cuzick J, Sestak I, Bianco A, Strobbe L, Bergh J, Hanusch C, Neven P, Dowsett M, Forbes JF, Buzdar A, Smith R, Howell A Long-term comparison of anastrozole versus tamoxifen: Results from LATTE/ATAC. vol.77, () .
10.1158/1538-7445.SABCS16-P2-09-03
CANCER RESEARCH2017
Smith SG, Sestak I, Forbes J, Howell A, Cuzick JJ Menopausal symptoms as predictors of long-term adherence in the International breast cancer intervention study (IBIS-1). vol.77, () .
10.1158/1538-7445.SABCS16-S5-03
CANCER RESEARCH2017
Thorat MA, Wagner S, Jones LJ, Levey PM, Bulka K, Hoff R, Sangale Z, II FDD, Bundred NJ, Fentiman IS, Forbes JF, Lanchbury JS, Cuzick J Prognostic and predictive relevance of cell cycle progression (CCP) score in ductal carcinoma in situ: Results from the UK/ANZ DCIS trial. vol.77, () .
10.1158/1538-7445.SABCS16-P1-09-06
CANCER RESEARCH2017
Berney D, Ahmad A, Parameshwaran V, Scardino P, Moller H, Cuzick J, Beltran L Should Reporting of Peri-Neural Invasion and Extra-Capsular Extension Be Mandatory in Prostate Cancer BiopsieS? Correlation with Outcome in 988 Cases Treated Conservatively. vol.97, () 214A - 214A.LABORATORY INVESTIGATION2017
Arbyn M, Xu L, Verdoodt F, Cuzick J, Szarewski A, Belinson JL, Wentzensen N, Gage JC, Khan MJ Genotyping for Human Papillomavirus Types 16 and 18 in Women With Minor Cervical Lesions: A Systematic Review and Meta-analysis.. vol.166, (2) 118 - 127.
10.7326/M15-2735
Ann Intern Med2017
Nair KP, Harkness EF, Gadde S, Lim YY, Maxwell AJ, Moschidis E, Foden P, Cuzick J, Brentnall A, Evans DG, Howell A, Astley SM The impact of using weight estimated from mammographic images vs self-reported weight on breast cancer risk calculation. vol.10134, () .
10.1117/12.2255619
MEDICAL IMAGING 2017: COMPUTER-AIDED DIAGNOSIS2017
cuzick J, BRENTNALL AR, segal C, Byers H, Reuter C, Detre S, Lopez-Knowles E, Sestak I, Howell A, Powles TJ, Newman WG, Dowsett M Impact of a panel of 88 SNPs on the risk of breast cancer in high risk women: Results from two randomised tamoxifen prevention trials. vol., () .
10.1200/JCO.2016.70.9386
Journal of Clinical Oncology2016
Castellsagué X, Ault KA, Bosch FX, Brown D, Cuzick J, Ferris DG, Joura EA, Garland SM, Giuliano AR, Hernandez-Avila M, Huh W, Iversen OE, Kjaer SK, Luna J, Monsonego J, Muñoz N, Myers E, Paavonen J, Pitisuttihum P, Steben M Human papillomavirus detection in cervical neoplasia attributed to 12 high-risk human papillomavirus genotypes by region. vol.2, () 61 - 69.
10.1016/j.pvr.2016.03.002
Papillomavirus Research2016
Gage JC, Hunt WC, Schiffman M, Katki HA, Cheung LA, Myers O, Cuzick J, Wentzensen N, Kinney W, Castle PE, Wheeler CM, New Mexico HPV Pap Registry Steering Committee Similar Risk Patterns After Cervical Screening in Two Large U.S. Populations: Implications for Clinical Guidelines.. vol.128, (6) 1248 - 1257.
10.1097/AOG.0000000000001721
Obstet Gynecol2016
Ahmad AS, Vasiljevi¿ N, Carter P, Berney DM, Møller H, Foster CS, Cuzick J, Lorincz AT A novel DNA methylation score accurately predicts death from prostate cancer in men with low to intermediate clinical risk factors.. vol.7, (44) 71833 - 71840.
10.18632/oncotarget.12377
Oncotarget2016
Buus R, Sestak I, Kronenwett R, Denkert C, Dubsky P, Krappmann K, Scheer M, Petry C, Cuzick J, Dowsett M Comparison of EndoPredict and EPclin With Oncotype DX Recurrence Score for Prediction of Risk of Distant Recurrence After Endocrine Therapy.. vol.108, (11) .
10.1093/jnci/djw149
Journal of the National Cancer Institute2016
Smith S, Foy R, McGowan J, Kobayashi L, Burn J, Brown K, Side L, Cuzick J General practitioner attitudes towards prescribing aspirin to carriers of Lynch Syndrome: Findings from a national survey. vol.42, (11) S233 - S233.
10.1016/j.ejso.2016.07.070
European Journal of Surgical Oncology (EJSO)2016
Evans DG, Brentnall A, Byers H, Harkness E, Stavrinos P, Howell A, FH-risk study Group , Newman WG, Cuzick J The impact of a panel of 18 SNPs on breast cancer risk in women attending a UK familial screening clinic: a case-control study.. vol., () .
10.1136/jmedgenet-2016-104125
Journal of Medical Genetics2016
Parameshwaran V, North BV, Moller H, Scardino P, Cuzick J, Beltran L, Berney DM The Significance of Reporting Perineural Invasion in 988 Conservatively Treated Prostate Cancer Patients with Long Term Outcome. vol.240, () 21 - 21.JOURNAL OF PATHOLOGY2016
Timms K, Cuzick J, Neff C, Reid J, Solimeno C, Sangale Z, Pruss D, Gutin A, Lanchbury J, Stone S The molecular landscape of genome instability in prostate cancer (PC). vol.27, () .
10.1093/annonc/mdw363.63
ANNALS OF ONCOLOGY2016
Cuzick J, Ahmad AS, Austin J, Cadman L, Ho L, Terry G, Kleeman M, Ashdown-Barr L, Lyons D, Stoler M, Szarewski A A comparison of different human papillomavirus tests in PreservCyt versus SurePath in a referral population—PREDICTORS 4. vol.82, () 145 - 151.
10.1016/j.jcv.2016.06.015
Journal of Clinical Virology2016
Sestak I, Zhang Y, Schroeder BE, Schnabel CA, Dowsett M, Cuzick J, Sgroi D Cross Stratification and Differential Risk by Breast Cancer Index and Recurrence Score in women with hormone receptor positive lymph-node negative early stage breast cancer. vol.22, (18) .
10.1158/1078-0432.CCR-16-0155
Clinical Cancer Research2016
Rudolph SE, Lorincz A, Wheeler CM, Gravitt P, Lazcano-Ponce E, Torres-Ibarra L, León-Maldonado L, Ramírez P, Rivera B, Hernández R, Franco EL, Cuzick J, Méndez-Hernández P, Salmerón J, FRIDA Study Group Population-based prevalence of cervical infection with human papillomavirus genotypes 16 and 18 and other high risk types in Tlaxcala, Mexico.. vol.16, () 461 - 461.
10.1186/s12879-016-1782-x
BMC Infect Dis2016
McDonald YJ, Goldberg DW, Scarinci IC, Castle PE, Cuzick J, Robertson M, Wheeler CM Health Service Accessibility and Risk in Cervical Cancer Prevention: Comparing Rural Versus Nonrural Residence in New Mexico.. vol., () .
10.1111/jrh.12202
Journal of Rural Health2016
Sestak I, Dowsett M, Ferree S, Baehner FL, Cuzick J Retrospective analysis of molecular scores for the prediction of distant recurrence according to baseline risk factors. vol.159, (1) .
10.1007/s10549-016-3868-y
Breast Cancer Research and Treatment2016
Moreira ED, Block SL, Ferris D, Giuliano AR, Iversen O-E, Joura EA, Kosalaraksa P, Schilling A, Van Damme P, Bornstein J, Bosch FX, Pils S, Cuzick J, Garland SM, Huh W, Kjaer SK, Qi H, Hyatt D, Martin J, Moeller E Safety Profile of the 9-Valent HPV Vaccine: A Combined Analysis of 7 Phase III Clinical Trials.. vol.138, (2) .
10.1542/peds.2015-4387
Pediatrics2016
Stankiewicz E, Mao X, Mangham DC, Xu L, Fisher G, North B, Moller H, Scardino P, Cuzick J, Berney D, Lu Y-J Identification of FBXL4 as a bone metastasis-associated gene in prostate cancer. vol.76, () .
10.1158/1538-7445.AM2016-1614
CANCER RESEARCH2016
Sasieni PD, Duffy SW, Cuzick J Ovarian cancer screening: UKCTOCS trial.. vol.387, (10038) 2602.
10.1016/S0140-6736(16)30847-9
Lancet2016
Cuzick J, Stone S, Fisher G, Yang ZH, North BV, Berney DM, Beltran L, Greenberg D, Moller H, Reid JE, Gutin A, Lanchbury JS, Brawer M, Scardino P Re: Validation of an RNA Cell Cycle Progression Score for Predicting Death from Prostate Cancer in a Conservatively Managed Needle Biopsy Cohort Editorial Comment. vol.195, (6) 1779 - 1780.
10.1016/j.juro.2016.03.057
JOURNAL OF UROLOGY2016
Lorincz AT, Brentnall AR, Scibior-Bentkowska D, Reuter C, Banwait R, Cadman L, Austin J, Cuzick J, Vasiljevi¿ N Validation of a DNA methylation HPV triage classifier in a screening sample.. vol.138, (11) 2745 - 2751.
10.1002/ijc.30008
Int J Cancer2016
Sestak I, Yeo B, Dodson A, Dowsett M, Cuzick JM Improved use of clinical variables for prognosis of distant recurrence in patients with ER plus breast cancer treated with 5 years endocrine therapy.. vol.34, (15) .
10.1200/JCO.2016.34.15_suppl.566
JOURNAL OF CLINICAL ONCOLOGY2016
Zdenkowski N, Forbes JF, Boyle FM, Kannourakis G, Gill PG, Bayliss E, Saunders C, Della-Fiorentina S, Kling N, Campbell I, Mann GB, Coates AS, Gebski V, Davies L, Thornton R, Reaby L, Cuzick J, Green M, Australia and New Zealand Breast Cancer Trials Group Observation versus late reintroduction of letrozole as adjuvant endocrine therapy for hormone receptor-positive breast cancer (ANZ0501 LATER): an open-label randomised, controlled trial.. vol.27, (5) 806 - 812.
10.1093/annonc/mdw055
Ann Oncol2016
Paleari L, Puntoni M, Clavarezza M, DeCensi M, Cuzick J, DeCensi A PIK3CA Mutation, Aspirin Use after Diagnosis and Survival of Colorectal Cancer. A Systematic Review and Meta-analysis of Epidemiological Studies. vol.28, (5) 317 - 326.
10.1016/j.clon.2015.11.008
Clinical Oncology2016
Evans DGR, Donnelly LS, Harkness EF, Astley SM, Stavrinos P, Dawe S, Watterson D, Fox L, Sergeant JC, Ingham S, Harvie MN, Wilson M, Beetles U, Buchan I, Brentnall AR, French DP, Cuzick J, Howell A Breast cancer risk feedback to women in the UK NHS breast screening population.. vol.114, (9) 1045 - 1052.
10.1038/bjc.2016.56
Br J Cancer2016
Berney DM, Beltran L, Fisher G, North BV, Greenberg D, Møller H, Soosay G, Scardino P, Cuzick J Validation of a contemporary prostate cancer grading system using prostate cancer death as outcome. vol.114, () 1068 - 1083.
10.1038/bjc.2016.86
British Journal of Cancer2016
Smith SG, Sestak I, Forster A, Partridge A, Side L, Wolf MS, Horne R, Wardle J, Cuzick J Factors affecting uptake and adherence to breast cancer chemoprevention: a systematic review and meta-analysis.. vol.27, (4) 575 - 590.
10.1093/annonc/mdv590
Ann Oncol2016
Salmerón J, Torres-Ibarra L, Bosch FX, Cuzick J, Lörincz A, Wheeler CM, Castle PE, Robles C, Lazcano-Ponce E HPV vaccination impact on a cervical cancer screening program: methods of the FASTER-Tlalpan Study in Mexico.. vol.58, (2) 211 - 219.
10.21149/spm.v58i2.7790
Salud Publica Mex2016
Bishoff J, Freedland S, Schlomm T, Reid J, Brawer M, Stone S, Cuzick J THE CCP SCORE PROVIDES SIGNIFICANT PROGNOSTIC INFORMATION IN GLEASON SCORE < 7 PATIENTS. vol.195, (4) E18 - E18.JOURNAL OF UROLOGY2016
Torres-Ibarra L, Lazcano-Ponce E, Franco EL, Cuzick J, Hernández-Ávila M, Lorincz A, Rivera B, Ramírez P, Mendiola-Pastrana I, Rudolph SE, León-Maldonado L, Hernández R, Barrios E, Gravitt P, Moscicki AB, Schmeler KM, Flores YN, Méndez-Hernández P, Salmerón J, FRIDA Study Group Triage strategies in cervical cancer detection in Mexico: methods of the FRIDA Study.. vol.58, (2) 197 - 210.
10.21149/spm.v58i2.7789
Salud Publica Mex2016
Massat NJ, Sasieni PD, Tataru D, Parmar D, Cuzick J, Duffy SW Explaining the Better Prognosis of Screening-Exposed Breast Cancers: Influence of Tumor Characteristics and Treatment.. vol.25, (3) 479 - 487.
10.1158/1055-9965.EPI-15-0804
Cancer Epidemiol Biomarkers Prev2016
Massat NJ, Dibden A, Parmar D, Cuzick J, Sasieni PD, Duffy SW Impact of Screening on Breast Cancer Mortality: The UK Program 20 Years On.. vol.25, (3) 455 - 462.
10.1158/1055-9965.EPI-15-0803
Cancer Epidemiol Biomarkers Prev2016
Forbes JF, Sestak I, Howell A, Bonanni B, Bundred N, Levy C, von Minckwitz G, Eiermann W, Neven P, Stierer M, Holcombe C, Coleman RE, Jones L, Ellis I, Cuzick J, IBIS-II investigators Anastrozole versus tamoxifen for the prevention of locoregional and contralateral breast cancer in postmenopausal women with locally excised ductal carcinoma in situ (IBIS-II DCIS): a double-blind, randomised controlled trial.. vol.387, (10021) 866 - 873.
10.1016/S0140-6736(15)01129-0
Lancet2016
Cuzick J, Forbes JF, Sestak I, Howell A, Bonanni B, Bundred N, Levy C, von Minckwitz G, Eiermann W, Neven P, Stierer M, Holcombe C, Coleman RE, Jones LJ, Ellis I Anastrozole versus tamoxifen for the prevention of loco-regional and contralateral breast cancer in postmenopausal women with locally excised ductal carcinoma in-situ (IBIS-II DCIS). vol.76, () .
10.1158/1538-7445.SABCS15-S6-03
CANCER RESEARCH2016
Dowsett M, Sestak I, Buus R, Kronenwett R, Denkert C, Krappmann K, Scheer M, Petry C, Dubsky P, Cuzick J EndoPredict (EPclin) score for estimating residual distant recurrence (DR) risk in ER+/HER2-breast cancer (br ca) patients treated with 5 years adjuvant endocrine therapy alone: Validation and comparison with the oncotype DX recurrence score (RS). vol.76, () .
10.1158/1538-7445.SABCS15-S3-01
CANCER RESEARCH2016
Smith SG, Sestak I, Forster A, Partridge A, Side L, Horne R, Wardle J, Cuzick J Factors affecting uptake and adherence to breast cancer chemoprevention: A systematic review and meta-analysis. vol.76, () .
10.1158/1538-7445.SABCS15-PD1-08
CANCER RESEARCH2016
Bartlett JMS, Ahmed I, Regan MM, Sestak I, Mallon EA, Dell'Orto P, Thurlimann BJK, Seynaeve C, Putter H, Brookes CL, Forbes JF, Colleoni MA, Bayani J, van de Velde CJH, Viale G, Cuzick J, Dowsett M, Rea DW, Inhibitor TA HER2 status as predictive marker for Al vs Tam benefit: A TRANS-AIOG meta-analysis of 12129 patients from ATAC, BIG 1-98 and TEAM with centrally determined HER2. vol.76, () .
10.1158/1538-7445.SABCS15-S4-06
CANCER RESEARCH2016
Sestak I, Zhang Y, Schroeder B, Dowsett M, Sgroi D, Cuzick J, Schnabel CA Integration of tumor size and grade with the breast cancer index (BCI) for prediction of distant recurrence in hormone receptor-positive breast cancer with 1-3 positive lymph nodes. vol.76, () .CANCER RESEARCH2016
Sestak I, Zhang Y, Schroeder B, Dowsett M, Sgroi D, Cuzick J, Schnabel CA Integration of tumor size and grade with the breast cancer index (BCl) for prediction of distant recurrence in hormone receptor-positive breast cancer with 1-3 positive lymph nodes. vol.76, () .CANCER RESEARCH2016
Evans DG, Astley SM, Brentnall A, Howell A, Cuzick J Mammographic density and SNPs add to Tyrer-Cuzick and Gail model breast cancer risk in a UK screening cohort. vol.76, () .
10.1158/1538-7445.SABCS15-PD1-07
CANCER RESEARCH2016
Thorat MA, Wagner S, Jones LJ, Levey PM, Bulka K, Hoff R, Sangale Z, II FDD, Bundred NJ, Fentiman IS, Forbes JF, Lanchbury JS, Cuzick J Prognostic and predictive relevance of HER2 status in ductal carcinoma in situ: Results from the UK/ANZ DCIS trial. vol.76, () .CANCER RESEARCH2016
Zhang Y, Sestak I, Schroeder BE, Dowsett M, Cuzick J, Schnabel CA, Sgroi DC Prognostic impact of the combined risk groups by breast cancer index and HOXB13/IL17BR ratio in hormonal receptor positive, node negative breast cancer: A TransATAC study. vol.76, () .CANCER RESEARCH2016
Thorat MA, Jones LJ, Levey PM, Elia G, Evagora CA, Bundred NJ, Fentiman IS, Forbes JF, Cuzick J Prognostic role and impact of multi -clonal ER and PgR expression in ductal carcinoma in situ: Results from the UK/ANZ DCIS trial. vol.76, () .CANCER RESEARCH2016
Thorat MA, Jones LJ, Levey PM, Elia G, Evagora CA, Bundred NJ, Fentiman IS, Forbes JF, Cuzick J Prognostic role and impact of multi-clonal ER and PgR expression in ductal carcinoma in situ: Results from the UK/ANZ DCIS trial. vol.76, () .
10.1158/1538-7445.SABCS15-P3-07-01
CANCER RESEARCH2016
Meyskens FL, Mukhtar H, Rock CL, Cuzick J, Kensler TW, Yang CS, Ramsey SD, Lippman SM, Alberts DS Cancer Prevention: Obstacles, Challenges and the Road Ahead.. vol.108, (2) .
10.1093/jnci/djv309
J Natl Cancer Inst2016
Cuzick J, Wickerham L, Powles T Differing Perspectives on Breast Cancer Chemoprevention.. vol.2, (2) 276 - 277.
10.1001/jamaoncol.2015.4406
JAMA Oncol2016
Berney D, Fisher G, North B, Moller H, Scardino P, Cuzick J, Beltran L Validation of Reporting Percentage High Grade Prostate Cancer in 988 Conservatively Treated Patients with Long Term Outcome. vol.96, () 217A - 217A.LABORATORY INVESTIGATION2016
Collins IM, Bickerstaffe A, Ranaweera T, Maddumarachchi S, Keogh L, Emery J, Mann GB, Butow P, Weideman P, Steel E, Trainer A, Bressel M, Hopper JL, Cuzick J, Antoniou AC, Phillips K-A iPrevent®: a tailored, web-based, decision support tool for breast cancer risk assessment and management.. vol.156, (1) 171 - 182.
10.1007/s10549-016-3726-y
Breast Cancer Res Treat2016
Vélez R, Turesson I, Landgren O, Kristinsson SY, Cuzick J Incidence of multiple myeloma in Great Britain, Sweden, and Malmö, Sweden: the impact of differences in case ascertainment on observed incidence trends.. vol.6, (1) e009584.
10.1136/bmjopen-2015-009584
BMJ Open2016
Spagnolo F, Sestak I, Howell A, Forbes JF, Cuzick J Anastrozole-Induced Carpal Tunnel Syndrome: Results From the International Breast Cancer Intervention Study II Prevention Trial. vol.34, (2) 139 - 143.
10.1200/JCO.2015.63.4972
Journal of Clinical Oncology2016
Scardino PT, Cuzick JM, Stone S, Evans B, Jorgensen MR, Eastham JA, Keane TE, Davis JW, Lin DW, Moul JW, Brawer MK, Crawford ED Application of active surveillance threshold to series of samples submitted for commercial testing.. vol.34, (2) .JOURNAL OF CLINICAL ONCOLOGY2016
Gage JC, Hunt WC, Schiffman M, Katki HA, Cheung LC, Cuzick J, Myers O, Castle PE, Wheeler CM, New Mexico HPV Pap Registry Steering Committee Risk Stratification Using Human Papillomavirus Testing among Women with Equivocally Abnormal Cytology: Results from a State-Wide Surveillance Program.. vol.25, (1) 36 - 42.
10.1158/1055-9965.EPI-15-0669
Cancer Epidemiol Biomarkers Prev2016
Phillips K-A, Steel EJ, Collins I, Emery J, Pirotta M, Mann GB, Butow P, Hopper JL, Trainer A, Moreton J, Antoniou AC, Cuzick J, Keogh L Transitioning to routine breast cancer risk assessment and management in primary care: what can we learn from cardiovascular disease?. vol.22, (3) 255 - 261.
10.1071/PY14156
Aust J Prim Health2016
Brentnall AR, Harkness EF, Astley SM, Donnelly LS, Stavrinos P, Sampson S, Fox L, Sergeant JC, Harvie MN, Wilson M, Beetles U, Gadde S, Lim Y, Jain A, Bundred S, Barr N, Reece V, Howell A, Cuzick J, Evans DGR Mammographic density adds accuracy to both the Tyrer-Cuzick and Gail breast cancer risk models in a prospective UK screening cohort. vol.17, (1) .
10.1186/s13058-015-0653-5
Breast Cancer Research2015
Brentnall AR, Harkness EF, Astley SM, Donnelly LS, Stavrinos P, Sampson S, Fox L, Sergeant JC, Harvie MN, Wilson M, Beetles U, Gadde S, Lim Y, Jain A, Bundred S, Barr N, Reece V, Howell A, Cuzick J, Evans DGR Mammographic density adds accuracy to both the Tyrer-Cuzick and Gail breast cancer risk models in a prospective UK screening cohort.. vol.17, (1) 147.
10.1186/s13058-015-0653-5
Breast Cancer Res2015
Cuzick J, Cuschieri K, Denton K, Hopkins M, Thorat MA, Wright C, Cubie H, Moore C, Kleeman M, Austin J, Ashdown-Barr L, Hunt K, Cadman L Performance of the Xpert HPV assay in women attending for cervical screening. vol.1, () 32 - 37.
10.1016/j.pvr.2015.05.002
Papillomavirus Research2015
Cuzick J Statistical controversies in clinical research: long-term follow-up of clinical trials in cancer.. vol.26, (12) 2363 - 2366.
10.1093/annonc/mdv392
Ann Oncol2015
Cuzick J, Sestak I, Thorat MA Impact of preventive therapy on the risk of breast cancer among women with benign breast disease.. vol.24 Suppl 2, () S51 - S55.
10.1016/j.breast.2015.07.013
Breast2015
Kim JJ, Campos NG, Sy S, Burger EA, Cuzick J, Castle PE, Hunt WC, Waxman A, Wheeler CM, New Mexico HPV Pap Registry Steering Committee Inefficiencies and High-Value Improvements in U.S. Cervical Cancer Screening Practice: A Cost-Effectiveness Analysis.. vol.163, (8) 589 - 597.
10.7326/M15-0420
Ann Intern Med2015
Early Breast Cancer Trialists' Collaborative Group (EBCTCG) Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials.. vol.386, (10001) 1341 - 1352.
10.1016/S0140-6736(15)61074-1
Lancet2015
DeCensi A, Puntoni M, Guerrieri-Gonzaga A, Cazzaniga M, Serrano D, Lazzeroni M, Vingiani A, Gentilini O, Petrera M, Viale G, Cuzick J, Bonanni B, Pruneri G Effect of Metformin on Breast Ductal Carcinoma In Situ Proliferation in a Randomized Presurgical Trial.. vol.8, (10) 888 - 894.
10.1158/1940-6207.CAPR-15-0048
Cancer Prev Res (Phila)2015
Paleari L, Puntoni M, Clavarezza M, Corradengo D, Campazzi E, Caviglia S, Provinciali N, Cuzick J, DeCensi A PIK3CA mutation, aspirin use after diagnosis and survival of colorectal cancer. A systematic review and meta-analysis of epidemiological studies. vol.26, () 36 - 36.ANNALS OF ONCOLOGY2015
Reid JL, Wright TC, Stoler MH, Cuzick J, Castle PE, Dockter J, Getman D, Giachetti C Human papillomavirus oncogenic mRNA testing for cervical cancer screening: baseline and longitudinal results from the CLEAR study.. vol.144, (3) 473 - 483.
10.1309/AJCPHVD7MIP3FYVV
Am J Clin Pathol2015
Gnant M, Sestak I, Filipits M, Dowsett M, Balic M, Lopez-Knowles E, Greil R, Dubsky P, Stoeger H, Rudas M, Jakesz R, Ferree S, Cowens JW, Nielsen T, Schaper C, Fesl C, Cuzick J Identifying clinically relevant prognostic subgroups of postmenopausal women with node-positive hormone receptor-positive early-stage breast cancer treated with endocrine therapy: a combined analysis of ABCSG-8 and ATAC using the PAM50 risk of recurrence score and intrinsic subtype.. vol.26, (8) 1685 - 1691.
10.1093/annonc/mdv215
Ann Oncol2015
Haviland JS, Bliss JM, Bentzen SM, Cuzick J In Regard to Vaidya et al.. vol.92, (5) 954 - 955.
10.1016/j.ijrobp.2015.05.026
Int J Radiat Oncol Biol Phys2015
Cuzick J, Stone S, Fisher G, Yang ZH, North BV, Berney DM, Beltran L, Greenberg D, Møller H, Reid JE, Gutin A, Lanchbury JS, Brawer M, Scardino P Validation of an RNA cell cycle progression score for predicting death from prostate cancer in a conservatively managed needle biopsy cohort.. vol.113, (3) 382 - 389.
10.1038/bjc.2015.223
Br J Cancer2015
Joura EA, Giuliano AR, Iversen O-E, Bouchard C, Mao C, Mehlsen J, Moreira ED, Ngan Y, Petersen LK, Lazcano-Ponce E, Pitisuttithum P, Restrepo JA, Stuart G, Woelber L, Yang YC, Cuzick J, Garland SM, Huh W, Kjaer SK, Bautista OM A 9-Valent HPV Vaccine Against Infection and Intraepithelial Neoplasia in Women. vol.70, (7) 446 - 448.
10.1097/OGX.0000000000000206
OBSTETRICAL & GYNECOLOGICAL SURVEY2015
Trinh T, Christensen SE, Brand JS, Cuzick J, Czene K, Sjölander A, Bälter K, Hall P Background risk of breast cancer influences the association between alcohol consumption and mammographic density.. vol.113, (1) 159 - 165.
10.1038/bjc.2015.185
Br J Cancer2015
Dowsett M, Sestak I, Buus R, Lopez-Knowles E, Mallon E, Howell A, Forbes JF, Buzdar A, Cuzick J Estrogen Receptor Expression in 21-Gene Recurrence Score Predicts Increased Late Recurrence for Estrogen-Positive/HER2-Negative Breast Cancer.. vol.21, (12) 2763 - 2770.
10.1158/1078-0432.CCR-14-2842
Clin Cancer Res2015
Cuzick J, Myers O, Hunt WC, Saslow D, Castle PE, Kinney W, Waxman A, Robertson M, Wheeler CM, New Mexico HPV Pap Registry Steering Committee Human papillomavirus testing 2007-2012: co-testing and triage utilization and impact on subsequent clinical management.. vol.136, (12) 2854 - 2863.
10.1002/ijc.29337
Int J Cancer2015
Mote PA, Gompel A, Howe C, Hilton HN, Sestak I, Cuzick J, Dowsett M, Hugol D, Forgez P, Byth K, Graham JD, Clarke CL Progesterone receptor A predominance is a discriminator of benefit from endocrine therapy in the ATAC trial.. vol.151, (2) 309 - 318.
10.1007/s10549-015-3397-0
Breast Cancer Res Treat2015
Stoler MH, Ronnett BM, Joste NE, Hunt WC, Cuzick J, Wheeler CM, New Mexico HPV Pap Registry Steering Committee The Interpretive Variability of Cervical Biopsies and Its Relationship to HPV Status.. vol.39, (6) 729 - 736.
10.1097/PAS.0000000000000381
Am J Surg Pathol2015
Zhang Y, Sestak I, Cuzick JM, Dowsett M, Schnabel CA, Sgroi D Correlation of Breast Cancer Index HOXB13/IL17BR (H/I), ER, PR and HER2 and prediction of relative endocrine benefit from tamoxifen and anastrozole in HR plus breast cancer: A TransATAC study.. vol.33, (15) .JOURNAL OF CLINICAL ONCOLOGY2015
Cuzick JM, Stone S, Fisher G, North B, Berney DM, Beltran L, Greenberg D, Moller H, Reid JE, Gutin A, Lanchbury JS, Brawer MK, Scardino PT Validation of an active surveillance threshold for the CCP score in conservatively managed men with localized prostate cancer.. vol.33, (15) .JOURNAL OF CLINICAL ONCOLOGY2015
Cuzick J, Sestak I, Cawthorn S, Hamed H, Holli K, Howell A, Forbes JF 16 year long-term follow-up of the IBIS-I breast cancer prevention trial. vol.75, () .
10.1158/1538-7445.SABCS14-S3-07
CANCER RESEARCH2015
Sestak I, Zhang Y, Schroeder BE, Goss PE, Dowsett M, Sgroi DC, Schnabel CA, Cuzick J Integration of breast cancer index (BCI) with clinicopathological factors for prediction of distant recurrence in ER plus breast cancer. vol.75, () .
10.1158/1538-7445.SABCS14-P4-11-19
CANCER RESEARCH2015
Guerrieri-Gonzaga A, Macis D, Gandini S, Aristarco V, Johansson H, Bollani G, Roth T, Sandri M-T, Knox J, Cuzick J, Bonanni B Low serum adiponectin level is an independent risk factor of DCIS in postmenopausal women at increased risk of breast cancer. vol.75, () .CANCER RESEARCH2015
Hiscox S, Smith C, Nicholson RI, Gee J, Harris A, Bliss J, Kalaizak E, Sestak I, Dowsett M, Cuzick J, Ellis I, Barrett-Lee P Nuclear beta-catenin negativity predicts for late relapse in ER plus , tamoxifen-treated breast cancer. vol.75, () .
10.1158/1538-7445.SABCS14-P3-06-01
CANCER RESEARCH2015
Howell A, Astley S, Harkness E, Wiseman J, Fox J, Stavrinos P, Wilson M, Lim Y, Reece V, Beetles U, Jain A, Sergeant J, Cuzick J, Warren R, Evans G Predicting the effect of tamoxifen on the breast: Change in measures of breast density, serum markers and SNPs. vol.75, () .
10.1158/1538-7445.SABCS14-P5-12-01
CANCER RESEARCH2015
Sestak I, Howell A, Forbes JF, Neven P, Cuzick J Timing, severity and risk factors for arthralgia in the IBIS-II trial: A retrospective and exploratory analysis. vol.75, () .
10.1158/1538-7445.SABCS14-PD4-1
CANCER RESEARCH2015
Møller H, Roswall N, Van Hemelrijck M, Larsen SB, Cuzick J, Holmberg L, Overvad K, Tjønneland A Prostate cancer incidence, clinical stage and survival in relation to obesity: a prospective cohort study in Denmark.. vol.136, (8) 1940 - 1947.
10.1002/ijc.29238
Int J Cancer2015
Cuzick J Radiotherapy for breast cancer, the TARGIT-A trial (vol 383, pg 1716, 2014). vol.385, (9976) 1396 - 1396.LANCET2015
Trinh T, Eriksson M, Darabi H, Bonn SE, Brand JS, Cuzick J, Czene K, Sjölander A, Bälter K, Hall P Background risk of breast cancer and the association between physical activity and mammographic density.. vol.17, () 50.
10.1186/s13058-015-0565-4
Breast Cancer Res2015
Cuzick J, Stone S, Reid J, Fisher G, Moller H, Brawer M, Scardino P, Shore N PATIENT AUA RISK CLASSIFICATION BASED ON COMBINED CLINICAL CELL CYCLE RISK (CCR) SCORE. vol.193, (4) E3 - E3.JOURNAL OF UROLOGY2015
Cuzick J, Stone S, Fisher G, Yang ZH, North B, Berney D, Beltran L, Greenberg D, Moller H, Reid J, Gutin A, Lanchbury J, Brawer M, Scardino P VALIDATION OF AN ACTIVE SURVEILLANCE THRESHOLD FOR THE CCP SCORE IN CONSERVATIVELY MANAGED MEN WITH LOCALIZED PROSTATE CANCER. vol.193, (4) E4 - E4.JOURNAL OF UROLOGY2015
Brentnall AR, Cuzick J Atypical Hyperplasia of the Breast. vol.372, (13) 1269 - 1270.
10.1056/NEJMc1501046
NEW ENGLAND JOURNAL OF MEDICINE2015
Brentnall AR, Cuzick J Atypical hyperplasia of the breast.. vol.372, (13) 1269 - 1270.
10.1056/NEJMc1501046#SA1
N Engl J Med2015
Louvanto K, Franco EL, Ramanakumar AV, Vasiljevi¿ N, Scibior-Bentkowska D, Koushik A, Cuzick J, Coutlée F, Lorincz AT, Biomarkers of Cervical Cancer Risk Study Team Methylation of viral and host genes and severity of cervical lesions associated with human papillomavirus type 16.. vol.136, (6) E638 - E645.
10.1002/ijc.29196
Int J Cancer2015
Sestak I, Cuzick J, Dowsett M, Lopez-Knowles E, Filipits M, Dubsky P, Cowens JW, Ferree S, Schaper C, Fesl C, Gnant M Prediction of late distant recurrence after 5 years of endocrine treatment: a combined analysis of patients from the Austrian breast and colorectal cancer study group 8 and arimidex, tamoxifen alone or in combination randomized trials using the PAM50 risk of recurrence score.. vol.33, (8) 916 - 922.
10.1200/JCO.2014.55.6894
J Clin Oncol2015
Kylstra JW, Kalnoski M, Quay S, Chen S, Vo T, Cuzick J Nipple aspirate fluid (NAF) cytology in the IBIS-model prediction of breast cancer (BCA) risk. vol.24, () S68 - S69.BREAST2015
Cuzick J, Thorat M Preventing invasive breast cancer in women at high risk based on benign/in situ pathology. vol.24, () S11 - S11.BREAST2015
Stone S, Cuzick JM, Fisher G, Yang ZH, North B, Berney DM, Beltran L, Greenberg D, Moller H, Reid JE, Gutin A, Lanchbury JS, Brawer MK, Scardino PT Validation of an active surveillance threshold for the CCP score in conservatively managed men with localized prostate cancer.. vol.33, (7) .JOURNAL OF CLINICAL ONCOLOGY2015
Joura EA, Giuliano AR, Iversen O-E, Bouchard C, Mao C, Mehlsen J, Moreira ED, Ngan Y, Petersen LK, Lazcano-Ponce E, Pitisuttithum P, Restrepo JA, Stuart G, Woelber L, Yang YC, Cuzick J, Garland SM, Huh W, Kjaer SK, Bautista OM A 9-valent HPV vaccine against infection and intraepithelial neoplasia in women.. vol.372, (8) 711 - 723.
10.1056/NEJMoa1405044
N Engl J Med2015
Brentnall AR, Cuzick J, Field J, Duffy SW A concordance index for matched case-control studies with applications in cancer risk.. vol.34, (3) 396 - 405.
10.1002/sim.6335
Stat Med2015
Castle PE, Cuzick J, Stoler MH, Wright TC, Reid JL, Dockter J, Giachetti C, Getman D Detection of human papillomavirus 16, 18, and 45 in women with ASC-US cytology and the risk of cervical precancer: results from the CLEAR HPV study.. vol.143, (2) 160 - 167.
10.1309/AJCPLCD8TTOMLJTB
Am J Clin Pathol2015
Beltran L, North B, Fisher G, Moller H, Scardino P, Cuzick J, Berney D Long Term Outcome in a Biopsy Cohort of 988 Conservatively Treated Prostate Cancers. Evidence for Revised Gleason Grading and Use of the Worst Scoring Core. vol.95, () 207A - 208A.LABORATORY INVESTIGATION2015
Sestak I, Cuzick J Update on breast cancer risk prediction and prevention.. vol.27, (1) 92 - 97.
10.1097/GCO.0000000000000153
Curr Opin Obstet Gynecol2015
Sestak I, Cuzick J Markers for the identification of late breast cancer recurrence.. vol.17, () 10.
10.1186/s13058-015-0516-0
Breast Cancer Res2015
DeCensi A, Thorat MA, Bonanni B, Smith SG, Cuzick J Barriers to preventive therapy for breast and other major cancers and strategies to improve uptake.. vol.9, () 595.
10.3332/ecancer.2015.595
Ecancermedicalscience2015
Cuzick J, Thorat MA, Bosetti C, Brown PH, Burn J, Cook NR, Ford LG, Jacobs EJ, Jankowski JA, La Vecchia C, Law M, Meyskens F, Rothwell PM, Senn HJ, Umar A Estimates of benefits and harms of prophylactic use of aspirin in the general population.. vol.26, (1) 47 - 57.
10.1093/annonc/mdu225
Ann Oncol2015
Cuzick J Gardasil 9 joins the fight against cervix cancer.. vol.14, (8) 1047 - 1049.
10.1586/14760584.2015.1051470
Expert Rev Vaccines2015
Brentnall AR, Vasiljevic N, Scibior-Bentkowska D, Cadman L, Austin J, Cuzick J, Lorincz AT HPV33 DNA methylation measurement improves cervical pre-cancer risk estimation of an HPV16, HPV18, HPV31 and \textit{EPB41L3} methylation classifier.. vol.15, (5) 669 - 675.
10.3233/CBM-150507
Cancer Biomark2015
Cuzick J, Thorat MA PSA testing for prostate cancer screening--authors' reply.. vol.16, (1) e3.
10.1016/S1470-2045(14)71189-1
Lancet Oncol2015
Cuzick J, Sestak I, Cawthorn S, Hamed H, Holli K, Howell A, Forbes JF, IBIS-I Investigators Tamoxifen for prevention of breast cancer: extended long-term follow-up of the IBIS-I breast cancer prevention trial.. vol.16, (1) 67 - 75.
10.1016/S1470-2045(14)71171-4
Lancet Oncol2015
Almonte M, Ferreccio C, Luciani S, Gonzales M, Delgado JM, Santos C, Alvarez M, Cuzick J, Sasieni P Visual inspection after acetic acid (VIA) is highly heterogeneous in primary cervical screening in Amazonian Peru.. vol.10, (1) e0115355.
10.1371/journal.pone.0115355
PLoS One2015
Sestak I, Singh S, Cuzick J, Blake GM, Patel R, Gossiel F, Coleman R, Dowsett M, Forbes JF, Howell A, Eastell R Changes in bone mineral density at 3 years in postmenopausal women receiving anastrozole and risedronate in the IBIS-II bone substudy: an international, double-blind, randomised, placebo-controlled trial. vol.15, (13) 1460 - 1468.
10.1016/S1470-2045(14)71035-6
Lancet Oncology2014
Sestak I, Singh S, Cuzick J Changes in bone mineral density at 3 years in postmenopausal women receiving anastrozole and risedronate in the IBIS-II bone substudy: an international, doubleblind, randomised, placebo-controlled trial (vol 15, pg 1464, 2014). vol.15, (13) E587 - E587.LANCET ONCOLOGY2014
Yang Z, Cuzick J, Hunt WC, Wheeler CM Concurrence of multiple human papillomavirus infections in a large US population-based cohort.. vol.180, (11) 1066 - 1075.
10.1093/aje/kwu267
Am J Epidemiol2014
Cuzick J Endpoints for the evaluation of breast cancer treatments.. vol.106, (12) .
10.1093/jnci/dju323
J Natl Cancer Inst2014
Thorat MA, Cuzick J Reply to the Letter to the Editor "The harms of low-dose aspirin prophylaxis are overstated" by P. Elwood and G. Morgan. vol., () .
10.1093/annonc/mdu546
Annals of Oncology2014
Gage JC, Katki HA, Schiffman M, Castle PE, Fetterman B, Poitras NE, Lorey T, Cheung LC, Behrens C, Sharma A, Zhao F-H, Cuzick J, Yang ZH, Kinney WK The low risk of precancer after a screening result of human papillomavirus-negative/atypical squamous cells of undetermined significance papanicolaou and implications for clinical management.. vol.122, (11) 842 - 850.
10.1002/cncy.21463
Cancer Cytopathol2014
Warwick J, Birke H, Stone J, Warren RML, Pinney E, Brentnall AR, Duffy SW, Howell A, Cuzick J Mammographic breast density refines Tyrer-Cuzick estimates of breast cancer risk in high-risk women: findings from the placebo arm of the International Breast Cancer Intervention Study I.. vol.16, (5) 451.
10.1186/s13058-014-0451-5
Breast Cancer Res2014
Collins IM, Steel E, Mann GB, Emery JD, Bickerstaffe A, Trainer A, Butow P, Pirotta M, Antoniou AC, Cuzick J, Hopper J, Phillips K-A, Keogh LA Assessing and managing breast cancer risk: clinicians' current practice and future needs.. vol.23, (5) 644 - 650.
10.1016/j.breast.2014.06.014
Breast2014
Joura EA, Ault KA, Bosch FX, Brown D, Cuzick J, Ferris D, Garland SM, Giuliano AR, Hernandez-Avila M, Huh W, Iversen O-E, Kjaer SK, Luna J, Miller D, Monsonego J, Munoz N, Myers E, Paavonen J, Pitisuttithum P, Steben M Attribution of 12 high-risk human papillomavirus genotypes to infection and cervical disease.. vol.23, (10) 1997 - 2008.
10.1158/1055-9965.EPI-14-0410
Cancer Epidemiol Biomarkers Prev2014
Evans DG, Brentnall AR, Harvie M, Dawe S, Sergeant JC, Stavrinos P, Astley S, Wilson M, Ainsworth J, Cuzick J, Buchan I, Donnelly LS, Howell A Breast cancer risk in young women in the national breast screening programme: implications for applying NICE guidelines for additional screening and chemoprevention.. vol.7, (10) 993 - 1001.
10.1158/1940-6207.CAPR-14-0037
Cancer Prev Res (Phila)2014
Cuzick J, Thorat MA, Andriole G, Brawley OW, Brown PH, Culig Z, Eeles RA, Ford LG, Hamdy FC, Holmberg L, Ilic D, Key TJ, La Vecchia C, Lilja H, Marberger M, Meyskens FL, Minasian LM, Parker C, Parnes HL, Perner S Prevention and early detection of prostate cancer.. vol.15, (11) e484 - e492.
10.1016/S1470-2045(14)70211-6
Lancet Oncol2014
Brentnall AR, Vasiljevi¿ N, Scibior-Bentkowska D, Cadman L, Austin J, Szarewski A, Cuzick J, Lorincz AT A DNA methylation classifier of cervical precancer based on human papillomavirus and human genes.. vol.135, (6) 1425 - 1432.
10.1002/ijc.28790
Int J Cancer2014
Vasiljevi¿ N, Ahmad AS, Thorat MA, Fisher G, Berney DM, Møller H, Foster CS, Cuzick J, Lorincz AT DNA methylation gene-based models indicating independent poor outcome in prostate cancer.. vol.14, () 655.
10.1186/1471-2407-14-655
BMC Cancer2014
Cuzick J Editorial comment.. vol.192, (2) 414.
10.1016/j.juro.2014.02.2584
J Urol2014
Cuzick J Prognostic Utility of the Cell Cycle Progression Score Generated from Biopsy in Men Treated with Prostatectomy EDITORIAL COMMENT. vol.192, (2) 414 - 414.JOURNAL OF UROLOGY2014
Wheeler CM, Hunt WC, Cuzick J, Langsfeld E, Robertson M, Castle PE, New Mexico HPV Pap Registry Steering Committee The influence of type-specific human papillomavirus infections on the detection of cervical precancer and cancer: A population-based study of opportunistic cervical screening in the United States.. vol.135, (3) 624 - 634.
10.1002/ijc.28605
Int J Cancer2014
Juraskova I, Butow P, Bonner C, Bell ML, Smith AB, Seccombe M, Boyle F, Reaby L, Cuzick J, Forbes JF Improving decision making about clinical trial participation - a randomised controlled trial of a decision aid for women considering participation in the IBIS-II breast cancer prevention trial.. vol.111, (1) 1 - 7.
10.1038/bjc.2014.144
Br J Cancer2014
Cuzick J Progress in breast cancer prevention. vol.50, () S7 - S7.EUROPEAN JOURNAL OF CANCER2014
Sestak I, Zhang Y, Schnabel CA, Schroeder B, Ander ME, Goss PE, Cuzick JM, Dowsett M, Sgroi D Clinical impact of differential risk stratification by breast cancer index (BCI) versus recurrence score (RS) in HR plus early-stage breast cancer: A TransATAC study.. vol.32, (15) .JOURNAL OF CLINICAL ONCOLOGY2014
Forbes JF, Dowsett M, Bradley R, Ingle JN, Aihara T, Bliss JM, Boccardo FM, Coates AS, Coombes RC, Cuzick JM, Dubsky PC, Gnant M, Kaufmann M, Kilburn LS, Perrone F, Rea D, Thurlimann BJK, Van De Velde CJH, Davies C, Gray RG Patient-level meta-analysis of randomized trials of aromatase inhibitors (AI) versus tamoxifen (Tam).. vol.32, (15) .JOURNAL OF CLINICAL ONCOLOGY2014
Cuzick JM, Brentnall A, Segal C, Sestak I, Kealy R, Howell A, Powles TJ, Orr N, Newman WG, Dowsett M Use of a SNP panel to refine risk estimates in women at high risk of breast cancer: Results from two randomized tamoxifen prevention trials.. vol.32, (15) .JOURNAL OF CLINICAL ONCOLOGY2014
Cuzick JM, Stone S, Fisher G, Yang ZH, North B, Berney D, Beltran L, Greenberg D, Meller H, Reid JE, Gutin A, Lanchbury JS, Brawer MK, Scardino PT Validation of an RNA cell cycle progression (CCP) score for predicting prostate cancer death in a conservatively managed needle biopsy cohort.. vol.32, (15) .JOURNAL OF CLINICAL ONCOLOGY2014
Cuzick J Radiotherapy for breast cancer, the TARGIT-A trial.. vol.383, (9930) 1716.
10.1016/S0140-6736(14)60825-4
Lancet2014
Cuzick J, Myers O, Hunt WC, Robertson M, Joste NE, Castle PE, Benard VB, Wheeler CM, New Mexico HPV Pap Registry Steering Committee A population-based evaluation of cervical screening in the United States: 2008-2011.. vol.23, (5) 765 - 773.
10.1158/1055-9965.EPI-13-0973
Cancer Epidemiol Biomarkers Prev2014
Cuzick J, Ho L, Terry G, Kleeman M, Giddings M, Austin J, Cadman L, Ashdown-Barr L, Costa MJ, Szarewski A Individual detection of 14 high risk human papilloma virus genotypes by the PapType test for the prediction of high grade cervical lesions.. vol.60, (1) 44 - 49.
10.1016/j.jcv.2014.02.002
J Clin Virol2014
Donnelly LS, Evans DG, Wiseman J, Fox J, Greenhalgh R, Affen J, Juraskova I, Stavrinos P, Dawe S, Cuzick J, Howell A Uptake of tamoxifen in consecutive premenopausal women under surveillance in a high-risk breast cancer clinic.. vol.110, (7) 1681 - 1687.
10.1038/bjc.2014.109
Br J Cancer2014
Eastell R, Sestak I, Gossiel F, Patel R, Blake G, Coleman R, Howell A, Dowsett M, Forbes JF, Singh S, Cuzick J EFFECT OF AROMATASE INHIBITION ON BONE DENSITY AND BONE TURNOVER IN HEALTHY POSTMENOPAUSAL WOMEN: RESULTS OF THE INTERNATIONAL BREAST CANCER INTERVENTION STUDY II (IBIS-II). vol.25, () S281 - S281.OSTEOPOROSIS INTERNATIONAL2014
Cuzick J, Stone S, Yang ZH, Reid J, Fisher G, Berney D, Beltran L, Moller H, Greenberg D, Brawer M, Gutin A, Lanchbury J, Scardino P VALIDATION OF A 46-GENE CELL CYCLE PROGRESSION (CCP) RNA SIGNATURE FOR PREDICTING PROSTATE CANCER DEATH IN A CONSERVATIVELY MANAGED WATCHFUL WAITING NEEDLE BIOPSY COHORT. vol.191, (4) E936 - E936.JOURNAL OF UROLOGY2014
Cuzick J, Sestak I, Forbes JF, Investigators IBIS-II Anastrozole for prevention of breast cancer in high-risk postmenopausal women (IBIS-II): an international, double-blind, randomised placebo-controlled trial (vol 383, pg 1041, 2014). vol.383, (9922) 1040 - 1040.LANCET2014
Cuzick J, Sestak I, Forbes JF, Dowsett M, Knox J, Cawthorn S, Saunders C, Roche N, Mansel RE, von Minckwitz G, Bonanni B, Palva T, Howell A, IBIS-II investigators Anastrozole for prevention of breast cancer in high-risk postmenopausal women (IBIS-II): an international, double-blind, randomised placebo-controlled trial.. vol.383, (9922) 1041 - 1048.
10.1016/S0140-6736(13)62292-8
Lancet2014
Merson S, Yang ZH, Brewer D, Olmos D, Eichholz A, McCarthy F, Fisher G, Kovacs G, Berney DM, Foster CS, Møller H, Scardino P, Cuzick J, Cooper CS, Clark JP, Transatlantic Prostate Group Focal amplification of the androgen receptor gene in hormone-naive human prostate cancer.. vol.110, (6) 1655 - 1662.
10.1038/bjc.2014.13
Br J Cancer2014
Vasiljevi¿ N, Scibior-Bentkowska D, Brentnall A, Cuzick J, Lorincz A A comparison of methylation levels in HPV18, HPV31 and HPV33 genomes reveals similar associations with cervical precancers.. vol.59, (3) 161 - 166.
10.1016/j.jcv.2013.12.014
J Clin Virol2014
Evans G, Stavrinos P, Dawe S, Harvie M, Wilson M, Maxwell A, Brentnall A, Cuzick J, Astley S, Howell A Assessing individual breast cancer risk within the UK National Health Service Breast Screening Programme: First prospective results from PROCAS. vol.50, () S3 - S4.EUROPEAN JOURNAL OF CANCER2014
Kinney W, Hunt WC, Dinkelspiel H, Robertson M, Cuzick J, Wheeler CM, New Mexico HPV Pap Registry Steering Committee Cervical excisional treatment of young women: a population-based study.. vol.132, (3) 628 - 635.
10.1016/j.ygyno.2013.12.037
Gynecol Oncol2014
Vasiljevi¿ N, Scibior-Bentkowska D, Brentnall AR, Cuzick J, Lorincz AT Credentialing of DNA methylation assays for human genes as diagnostic biomarkers of cervical intraepithelial neoplasia in high-risk HPV positive women.. vol.132, (3) 709 - 714.
10.1016/j.ygyno.2014.02.001
Gynecol Oncol2014
Ejegod DM, Serrano I, Cuschieri KS, Nussbaumer WA, Vaughan LM, Ahmad AS, Cuzick J, Bonde J Inter and intra laboratory reproducibility of BD Onclarity HPV assay in ThinPrep primarily screening samples. vol.122, () 30 - 30.APMIS2014
Dowsett M, Sestak I, Buus R, Lopez-Knowles E, Cuzick J Oestrogen module of 21-gene recurrence score predicts increased late recurrence for ER+HER2-breast cancer. vol.50, () S105 - S106.EUROPEAN JOURNAL OF CANCER2014
Cuzick J The prevention of breast cancer. vol.50, () S34 - S35.EUROPEAN JOURNAL OF CANCER2014
Brentnall AR, Evans DG, Cuzick J Distribution of breast cancer risk from SNPs and classical risk factors in women of routine screening age in the UK.. vol.110, (3) 827 - 828.
10.1038/bjc.2013.747
Br J Cancer2014
Sestak I, Singh S, Cuzick J, Blake G, Patel R, Coleman R, Dowsett M, Forbes JF, Howell A, Eastell R Risedronate Prevents Anastrozole-Induced Bone Loss In The IBIS-II Prevention Trial.. vol.29, () S110 - S110.JOURNAL OF BONE AND MINERAL RESEARCH2014
Allen MD, Thomas GJ, Clark S, Dawoud MM, Vallath S, Payne SJ, Gomm JJ, Dreger SA, Dickinson S, Edwards DR, Pennington CJ, Sestak I, Cuzick J, Marshall JF, Hart IR, Jones JL Altered microenvironment promotes progression of preinvasive breast cancer: myoepithelial expression of αvβ6 integrin in DCIS identifies high-risk patients and predicts recurrence.. vol.20, (2) 344 - 357.
10.1158/1078-0432.CCR-13-1504
Clin Cancer Res2014
Castañón A, Landy R, Cuzick J, Sasieni P Cervical screening at age 50-64 years and the risk of cervical cancer at age 65 years and older: population-based case control study.. vol.11, (1) e1001585.
10.1371/journal.pmed.1001585
PLoS Med2014
Vasiljevi¿ N, Ahmad AS, Carter PD, Fisher G, Berney DM, Foster CS, Cuzick J, Lorincz AT DNA methylation of PITX2 predicts poor survival in men with prostate cancer.. vol.8, (9) 1143 - 1150.
10.2217/bmm.14.41
Biomark Med2014
Cuzick J, Thorat MA Preface. vol.202, () .
10.1007/s10555-010-9228-1
2014
Cuzick J Prognostic value of a cell cycle progression score for men with prostate cancer.. vol.202, () 133 - 140.
10.1007/978-3-642-45195-9_16
Recent Results Cancer Res2014
Thorat M, Cuzick J Prophylactic use of aspirin: systematic review of harms and approaches to mitigation in the general population. vol.30, (1) 5 - 18.
10.1007/s10654-014-9971-7
European Journal of Epidemiology2014
Bosch FX, Broker TR, Forman D, Moscicki AB, Gillison ML, Doorbar J, Stern PL, Stanley M, Arbyn M, Poljak M, Cuzick J, Castle PE, Schiller JT, Markowitz LE, Fisher WA, Canfell K, Denny LA, Franco EL, Steben M, Kane MA Comprehensive control of human papillomavirus infections and related diseases.. vol.31, () H1 - H31.
10.1016/j.vaccine.2013.10.003
Vaccine2013
Bosch FX, Broker TR, Forman D, Moscicki A-B, Gillison ML, Doorbar J, Stern PL, Stanley M, Arbyn M, Poljak M, Cuzick J, Castle PE, Schiller JT, Markowitz LE, Fisher WA, Canfell K, Denny LA, Franco EL, Steben M, Kane MA Comprehensive control of human papillomavirus infections and related diseases.. vol.31 Suppl 6, () G1 - 31.
10.1016/j.vaccine.2013.10.002
Vaccine2013
Bosch FX, Broker TR, Forman D, Moscicki A-B, Gillison ML, Doorbar J, Stern PL, Stanley M, Arbyn M, Poljak M, Cuzick J, Castle PE, Schiller JT, Markowitz LE, Fisher WA, Canfell K, Denny LA, Franco EL, Steben M, Kane MA Comprehensive control of human papillomavirus infections and related diseases.. vol.31 Suppl 5, () F1 - 31.
10.1016/j.vaccine.2013.10.001
Vaccine2013
Cuzick J, Sestak I, Forbes JF, Dowsett M, Knox J, Cawthorn S, Saunders C, Roche N, Mansel RE, von Minckwitz G, Bonanni B, Palva T, Howell A Breast cancer prevention using anastrozole in postmenopausal women at high risk. vol.73, () .
10.1158/0008-5472.SABCS13S3-01
CANCER RESEARCH2013
Sestak I, Cuzick J, Dowsett M, Filipits M, Dubsky P, Cowens W, Ferree S, Schaper C, Fesl C, Gnant M Prediction of late distant recurrence after 5 years of endocrine treatment: A combined analysis of 2485 patients from the ABCSG-8 and transATAC studies using the PAM50 risk of recurrence (ROR) score. vol.73, () .
10.1158/0008-5472.SABCS13-S6-04
CANCER RESEARCH2013
Cuzick J Duration of Aromatase Inhibitor Treatment in Breast Cancer: The Role of the 'Carryover Effect'. vol.27, (12) 1224 - 1225.ONCOLOGY-NEW YORK2013
Thorat MA, Cuzick J Role of aspirin in cancer prevention.. vol.15, (6) 533 - 540.
10.1007/s11912-013-0351-3
Curr Oncol Rep2013
Bosch FX, Broker TR, Forman D, Moscicki AB, Gillison ML, Doorbar J, Stern PL, Stanley M, Arbyn M, Poljak M, Cuzick J, Castle PE, Schiller JT, Markowitz LE, Fisher WA, Canfell K, Denny LA, Franco EL, Steben M, Kane MA Comprehensive Control of Human Papillomavirus Infections and Related Diseases. vol.31, (SUPPL.8) 11 - 131.
10.1016/j.vaccine.2013.07.026
Vaccine2013
Bosch FX, Broker TR, Forman D, Moscicki A-B, Gillison ML, Doorbar J, Stern PL, Stanley M, Arbyn M, Poljak M, Cuzick J, Castle PE, Schiller JT, Markowitz LE, Fisher WA, Canfell K, Denny LA, Franco EL, Steben M, Kane MA Comprehensive control of human papillomavirus infections and related diseases.. vol.31 Suppl 8, () I1 - 31.
10.1016/j.vaccine.2013.07.026
Vaccine2013
Cuzick J, Yang Z A frailty model for interaction between multiple events. vol.122, () 133 - 147.
10.1016/j.jmva.2013.07.012
JOURNAL OF MULTIVARIATE ANALYSIS2013
Sestak I, Dowsett M, Zabaglo L, Lopez-Knowles E, Ferree S, Cowens JW, Cuzick J Factors predicting late recurrence for estrogen receptor-positive breast cancer.. vol.105, (19) 1504 - 1511.
10.1093/jnci/djt244
J Natl Cancer Inst2013
Sgroi DC, Sestak I, Cuzick J, Zhang Y, Schnabel CA, Schroeder B, Erlander MG, Dunbier A, Sidhu K, Lopez-Knowles E, Goss PE, Dowsett M Prediction of late distant recurrence in patients with oestrogen-receptor-positive breast cancer: a prospective comparison of the breast-cancer index (BCI) assay, 21-gene recurrence score, and IHC4 in the TransATAC study population.. vol.14, (11) 1067 - 1076.
10.1016/S1470-2045(13)70387-5
Lancet Oncol2013
Collins IM, Keogh LA, Steel E, Emery J, Pirotta M, Mann B, Butow P, Trainer A, Moreton J, Antoniou AC, Cuzick JM, Hopper JL, Phillips K-A Assessing breast cancer risk in primary care: What can we learn from cardiovascular disease?. vol.31, (26) .JOURNAL OF CLINICAL ONCOLOGY2013
Cuzick J Should all men receive PSA screening?. vol.49, () S20 - S20.EUROPEAN JOURNAL OF CANCER2013
Visvanathan K, Hurley P, Bantug E, Brown P, Col NF, Cuzick J, Davidson NE, Decensi A, Fabian C, Ford L, Garber J, Katapodi M, Kramer B, Morrow M, Parker B, Runowicz C, Vogel VG, Wade JL, Lippman SM Use of pharmacologic interventions for breast cancer risk reduction: American Society of Clinical Oncology clinical practice guideline.. vol.31, (23) 2942 - 2962.
10.1200/JCO.2013.49.3122
J Clin Oncol2013
Dowsett M, Sestak I, Lopez-Knowles E, Sidhu K, Dunbier AK, Cowens JW, Ferree S, Storhoff J, Schaper C, Cuzick J Comparison of PAM50 risk of recurrence score with oncotype DX and IHC4 for predicting risk of distant recurrence after endocrine therapy.. vol.31, (22) 2783 - 2790.
10.1200/JCO.2012.46.1558
J Clin Oncol2013
Lorincz AT, Brentnall AR, Vasiljevi¿ N, Scibior-Bentkowska D, Castanon A, Fiander A, Powell N, Tristram A, Cuzick J, Sasieni P HPV16 L1 and L2 DNA methylation predicts high-grade cervical intraepithelial neoplasia in women with mildly abnormal cervical cytology.. vol.133, (3) 637 - 644.
10.1002/ijc.28050
Int J Cancer2013
Afentakis M, Dowsett M, Sestak I, Salter J, Howell T, Buzdar A, Forbes J, Cuzick J Immunohistochemical BAG1 expression improves the estimation of residual risk by IHC4 in postmenopausal patients treated with anastrazole or tamoxifen: a TransATAC study.. vol.140, (2) 253 - 262.
10.1007/s10549-013-2628-5
Breast Cancer Res Treat2013
Cuzick J, Yang ZH, Fisher G, Tikishvili E, Stone S, Lanchbury JS, Camacho N, Merson S, Brewer D, Cooper CS, Clark J, Berney DM, Møller H, Scardino P, Sangale Z, Transatlantic Prostate Group Prognostic value of PTEN loss in men with conservatively managed localised prostate cancer.. vol.108, (12) 2582 - 2589.
10.1038/bjc.2013.248
Br J Cancer2013
Mesher D, Szarewski A, Cadman L, Austin J, Ashdown-Barr L, Ho L, Terry G, Young M, Stoler M, Bergeron C, McCarthy J, Wright C, Liddle S, Soutter WP, Lyons D, Cuzick J Comparison of human papillomavirus testing strategies for triage of women referred with low-grade cytological abnormalities.. vol.49, (9) 2179 - 2186.
10.1016/j.ejca.2013.01.018
Eur J Cancer2013
Cuzick J, Sestak I, Bonanni B, Costantino JP, Cummings S, DeCensi A, Dowsett M, Forbes JF, Ford L, LaCroix AZ, Mershon J, Mitlak BH, Powles T, Veronesi U, Vogel V, Wickerham DL, SERM Chemoprevention of Breast Cancer Overview Group Selective oestrogen receptor modulators in prevention of breast cancer: an updated meta-analysis of individual participant data.. vol.381, (9880) 1827 - 1834.
10.1016/S0140-6736(13)60140-3
Lancet2013
Pugliano L, Zardavas D, Paesmans M, Sestak I, Gelber RD, Cuzick JM, Dowsett M, Awada A, Piccart-Gebhart MJ, De Azambuja E A meta-analysis of endocrine therapy trials in early breast cancer (BC) evaluating the impact of obesity: Are aromatase inhibitors (AIs) optimal therapy in obese ER plus BC?. vol.31, (15) .JOURNAL OF CLINICAL ONCOLOGY2013
Phillips K-A, Keogh LA, Steel E, Collins IM, Emery J, Pirotta M, Mann B, Butow P, Trainer A, Moreton J, Antoniou AC, Cuzick JM, Hopper JL Assessing breast cancer risk in primary care: What can we learn from cardiovascular disease?. vol.31, (15) .JOURNAL OF CLINICAL ONCOLOGY2013
Collins IM, Keogh LA, Steel E, Mann B, Emery J, Pirotta M, Moreton J, Butow P, Trainer A, Antoniou AC, Cuzick JM, Hopper JL, Phillips K-A Development of a tailored, computerized, breast cancer risk assessment and decision support tool: What do clinicians want?. vol.31, (15) .JOURNAL OF CLINICAL ONCOLOGY2013
Gnant M, Dowsett M, Filipits M, Lopez-Knowles E, Greil R, Balic M, Cowens JW, Nielsen TO, Shaper C, Sestak I, Fesl C, Cuzick JM, Canc ABC Identifying clinically relevant prognostic subgroups in node-positive postmenopausal HR plus early breast cancer patients treated with endocrine therapy: A combined analysis of 2,485 patients from ABCSG-8 and ATAC using the PAM50 risk of recurrence (ROR) score and intrinsic subtype. vol.31, (15) .JOURNAL OF CLINICAL ONCOLOGY2013
Brawer MK, Cuzick JM, Cooperberg MR, Swanson GP, Freedland SJ, Reid JE, Fisher G, Lanchbury JS, Gutin A, Stone S, Carroll P, Grp TP Prolaris: A novel genetic test for prostate cancer prognosis. vol.31, (15) .JOURNAL OF CLINICAL ONCOLOGY2013
Cuzick J, Cadman L, Mesher D, Austin J, Ashdown-Barr L, Ho L, Terry G, Liddle S, Wright C, Lyons D, Szarewski A Comparing the performance of six human papillomavirus tests in a screening population.. vol.108, (4) 908 - 913.
10.1038/bjc.2013.22
Br J Cancer2013
Vasiljevi¿ N, Ahmad AS, Beesley C, Thorat MA, Fisher G, Berney DM, Møller H, Yu Y, Lu Y-J, Cuzick J, Foster CS, Lorincz AT Association between DNA methylation of HSPB1 and death in low Gleason score prostate cancer.. vol.16, (1) 35 - 40.
10.1038/pcan.2012.47
Prostate Cancer Prostatic Dis2013
Cox JT, Castle PE, Behrens CM, Sharma A, Wright TC, Cuzick J, Athena HPV Study Group Comparison of cervical cancer screening strategies incorporating different combinations of cytology, HPV testing, and genotyping for HPV 16/18: results from the ATHENA HPV study.. vol.208, (3) 184.e1 - 184.e11.
10.1016/j.ajog.2012.11.020
Am J Obstet Gynecol2013
Brawer MK, Cooperberg MR, Freedland SJ, Swanson GP, Stone S, Reid JE, Gutin A, Carroll P, Cuzick JM Development and validation of a mutivariate model combining cell cycle progression score with CAPRA to predict prostate cancer mortality in a conservatively managed cohort. vol.31, (6) .JOURNAL OF CLINICAL ONCOLOGY2013
Cuzick J, Thomas Cox J, Zhang G, Einstein MH, Stoler M, Trupin S, Behrens CM Human papillomavirus testing for triage of women with low-grade squamous intraepithelial lesions.. vol.132, (4) 959 - 966.
10.1002/ijc.27723
Int J Cancer2013
Fisher G, Yang ZH, Kudahetti S, Møller H, Scardino P, Cuzick J, Berney DM, Transatlantic Prostate Group Prognostic value of Ki-67 for prostate cancer death in a conservatively managed cohort.. vol.108, (2) 271 - 277.
10.1038/bjc.2012.598
Br J Cancer2013
Stoler MH, Wright TC, Cuzick J, Dockter J, Reid JL, Getman D, Giachetti C APTIMA HPV assay performance in women with atypical squamous cells of undetermined significance cytology results.. vol.208, (2) 144.e1 - 144.e8.
10.1016/j.ajog.2012.12.003
Am J Obstet Gynecol2013
Eastell R, Sestak I, Gossiel F, Patel R, Blake G, Coleman R, Howell A, Dowsett M, Forbes J, Singh S, Cuzick J Effect of Aromatase Inhibition on Bone Density and Bone Turnover in Healthy Postmenopausal Women: Results of the International Breast cancer Intervention Study II (IBIS-II). vol.28, () .JOURNAL OF BONE AND MINERAL RESEARCH2013
Carozzi F, Gillio-Tos A, Confortini M, Del Mistro A, Sani C, De Marco L, Girlando S, Rosso S, Naldoni C, Dalla Palma P, Zorzi M, Giorgi-Rossi P, Segnan N, Cuzick J, Ronco G, NTCC working group Risk of high-grade cervical intraepithelial neoplasia during follow-up in HPV-positive women according to baseline p16-INK4A results: a prospective analysis of a nested substudy of the NTCC randomised controlled trial.. vol.14, (2) 168 - 176.
10.1016/S1470-2045(12)70529-6
Lancet Oncol2013
Ahmad I, Singh LB, Yang ZH, Kalna G, Fleming J, Fisher G, Cooper C, Cuzick J, Berney DM, Møller H, Scardino P, Leung HY Mir143 expression inversely correlates with nuclear ERK5 immunoreactivity in clinical prostate cancer.. vol.108, (1) 149 - 154.
10.1038/bjc.2012.510
Br J Cancer2013
Palva T, Ranta H, Koivisto A-M, Pylkkänen L, Cuzick J, Holli K A double-blind placebo-controlled study to evaluate endometrial safety and gynaecological symptoms in women treated for up to 5 years with tamoxifen or placebo - a substudy for IBIS I Breast Cancer Prevention Trial.. vol.49, (1) 45 - 51.
10.1016/j.ejca.2012.06.015
Eur J Cancer2013
Wheeler CM, Hunt WC, Cuzick J, Langsfeld E, Pearse A, Montoya GD, Robertson M, Shearman CA, Castle PE, New Mexico HPV Pap Registry Steering Committee A population-based study of human papillomavirus genotype prevalence in the United States: baseline measures prior to mass human papillomavirus vaccination.. vol.132, (1) 198 - 207.
10.1002/ijc.27608
Int J Cancer2013
von Karsa L, Patnick J, Segnan N, Atkin W, Halloran S, Lansdorp-Vogelaar I, Malila N, Minozzi S, Moss S, Quirke P, Steele RJ, Vieth M, Aabakken L, Altenhofen L, Ancelle-Park R, Antoljak N, Anttila A, Armaroli P, Arrossi S, Austoker J European guidelines for quality assurance in colorectal cancer screening and diagnosis: Overview and introduction to the full Supplement publication. vol.45, (1) 51 - 59.
10.1055/s-0032-1325997
ENDOSCOPY2013
Arbyn M, Roelens J, Cuschieri K, Cuzick J, Szarewski A, Ratnam S, Reuschenbach M, Belinson S, Belinson JL, Monsonego J The APTIMA HPV assay versus the Hybrid Capture 2 test in triage of women with ASC-US or LSIL cervical cytology: a meta-analysis of the diagnostic accuracy.. vol.132, (1) 101 - 108.
10.1002/ijc.27636
Int J Cancer2013
Sainsbury R, Loddo M, Proctor I, Stoeber K, Williams G, Thorat M, Cuzick J Cell cycle algorithm correlates with grade of DCIS and p53 status, allows elimination of 'intermediate grade' disease and gives clinically meanignful information.. vol.72, () .
10.1158/0008-5472.SABCS12-PD04-08
CANCER RESEARCH2012
Sgroi DC, Sestak I, Cuzick J, Zhang Y, Schnabel CA, Erlander MG, Goss PE, Dowsett M Comparative Performance of Breast Cancer Index (BCI) vs. Oncotype Dx and IHC4 in the Prediction of Late Recurrence in Hormonal Receptor-Positive Lymph Node-Negative Breast Cancer Patients: A TransATAC Study. vol.72, () .
10.1158/0008-5472.SABCS12-S1-9
CANCER RESEARCH2012
Sgroi DC, Sestak I, Zhang Y, Erlander MG, Schnabel CA, Goss PE, Cuzick J, Dowsett M Evaluation of Prognostic and Predictive Performance of Breast Cancer Index and Its Components in Hormonal Receptor-Positive Breast Cancer Patients: A TransATAC Study. vol.72, () .
10.1158/0008-5472.SABCS12-P2-10-15
CANCER RESEARCH2012
Motion J, Ashcroft L, Dowsett M, Cuzick J, Hickman J, Evans G, Eccles D, Eeles R, Greenhalgh R, Affen J, Bundred S, Boggis C, Sergeant J, Fallowfield L, Adams J, Howell A The RAZOR trial: a phase II prevention trial of screening plus goserilin and raloxifene versus screening alone in pre-menopausal women at increased risk of breast cancer.. vol.72, () .
10.1158/0008-5472.SABCS12-P1-09-05
CANCER RESEARCH2012
Sestak I, Cuzick J Preventive therapy for breast cancer.. vol.14, (6) 568 - 573.
10.1007/s11912-012-0273-5
Curr Oncol Rep2012
Cuzick J, Bergeron C, von Knebel Doeberitz M, Gravitt P, Jeronimo J, Lorincz AT, J L M Meijer C, Sankaranarayanan R, J F Snijders P, Szarewski A New technologies and procedures for cervical cancer screening.. vol.30 Suppl 5, () F107 - F116.
10.1016/j.vaccine.2012.05.088
Vaccine2012
Poljak M, Cuzick J, Kocjan BJ, Iftner T, Dillner J, Arbyn M Nucleic acid tests for the detection of alpha human papillomaviruses.. vol.30 Suppl 5, () F100 - F106.
10.1016/j.vaccine.2012.04.105
Vaccine2012
Rae JM, Hayes DF, Cuzick J, Sestak I, Dowsett M CYP2D6 and UGT2B7 Genotype and Risk of Recurrence in Tamoxifen-Treated Breast Cancer Patients (vol 104, pg 452, 2012). vol.104, (22) 1772 - 1772.
10.1093/jnci/djs443
JOURNAL OF THE NATIONAL CANCER INSTITUTE2012
Cuzick J HPV ELIMINATION OF CERVICAL CANCER: THE NOVEL OPTIONS IN VACCINATION AND SCREENING. vol.23, () 53 - 53.ANNALS OF ONCOLOGY2012
Cuzick J, Sestak I, Ferree S, Cowens JW, Dowsett M PREDICTION OF LATE BREAST CANCER RECURRENCE BY THE ROR (PAM50) SCORE IN POSTMENOPAUSAL WOMEN IN THE TRANSATAC COHORT. vol.23, () 75 - 76.ANNALS OF ONCOLOGY2012
Cuzick J Breast density predicts endocrine treatment outcome in the adjuvant setting.. vol.14, (4) 109.
10.1186/bcr3235
Breast Cancer Res2012
Jeetle SS, Fisher G, Yang ZH, Stankiewicz E, Møller H, Cooper CS, Cuzick J, Berney DM, Trans-Atlantic Prostate Group Neuroendocrine differentiation does not have independent prognostic value in conservatively treated prostate cancer.. vol.461, (2) 103 - 107.
10.1007/s00428-012-1259-2
Virchows Arch2012
Rae JM, Hayes DF, Cuzick J, Sestak I, Dowsett M Re: CYP2D6 Genotype and Tamoxifen Response in Postmenopausal Women With Endocrine-Responsive Breast Cancer: The Breast International Group 1-98 Trial Response. vol.104, (16) 1267 - 1268.
10.1093/jnci/djs302
JOURNAL OF THE NATIONAL CANCER INSTITUTE2012
Sestak I, Kealy R, Nikoloff M, Fontecha M, Forbes JF, Howell A, Cuzick J Relationships between CYP2D6 phenotype, breast cancer and hot flushes in women at high risk of breast cancer receiving prophylactic tamoxifen: results from the IBIS-I trial.. vol.107, (2) 230 - 233.
10.1038/bjc.2012.278
Br J Cancer2012
Evans DGR, Warwick J, Astley SM, Stavrinos P, Sahin S, Ingham S, McBurney H, Eckersley B, Harvie M, Wilson M, Beetles U, Warren R, Hufton A, Sergeant JC, Newman WG, Buchan I, Cuzick J, Howell A Assessing individual breast cancer risk within the U.K. National Health Service Breast Screening Program: a new paradigm for cancer prevention.. vol.5, (7) 943 - 951.
10.1158/1940-6207.CAPR-11-0458
Cancer Prev Res (Phila)2012
Sestak I, Harvie M, Howell A, Forbes JF, Dowsett M, Cuzick J Weight change associated with anastrozole and tamoxifen treatment in postmenopausal women with or at high risk of developing breast cancer.. vol.134, (2) 727 - 734.
10.1007/s10549-012-2085-6
Breast Cancer Res Treat2012
Bosetti C, Rosato V, Gallus S, Cuzick J, La Vecchia C Aspirin and cancer risk: a quantitative review to 2011.. vol.23, (6) 1403 - 1415.
10.1093/annonc/mds113
Ann Oncol2012
Szarewski A, Mesher D, Cadman L, Austin J, Ashdown-Barr L, Ho L, Terry G, Liddle S, Young M, Stoler M, McCarthy J, Wright C, Bergeron C, Soutter WP, Lyons D, Cuzick J Comparison of seven tests for high-grade cervical intraepithelial neoplasia in women with abnormal smears: the Predictors 2 study.. vol.50, (6) 1867 - 1873.
10.1128/JCM.00181-12
J Clin Microbiol2012
Stankiewicz E, Ng M, Cuzick J, Mesher D, Watkin N, Lam W, Corbishley C, Berney DM The prognostic value of Ki-67 expression in penile squamous cell carcinoma.. vol.65, (6) 534 - 537.
10.1136/jclinpath-2011-200638
J Clin Pathol2012
Howell A, Cuzick J Oestrogen and breast cancer: results from the WHI trial.. vol.13, (5) 437 - 438.
10.1016/S1470-2045(12)70110-9
Lancet Oncol2012
Ronco G, Biggeri A, Confortini M, Naldoni C, Segnan N, Sideri M, Zappa M, Zorzi M, Calvia M, Accetta G, Giordano L, Cogo C, Carozzi F, Gillio Tos A, Arbyn M, Mejier CJLM, Snijders PJF, Cuzick J, Giorgi Rossi P [Health technology assessment report: HPV DNA based primary screening for cervical cancer precursors].. vol.36, (3-4 Suppl 1) e1 - 72.Epidemiol Prev2012
Ronco G, Meijer CJL, Cuzick J, Giorgi-Rossi P, Peto J, Segnan N, Dillner J Screening for cervical cancer.. vol.156, (8) 604 - 605.
10.7326/0003-4819-156-8-201204170-00011
Ann Intern Med2012
Lundgren K, Brown M, Pineda S, Cuzick J, Salter J, Zabaglo L, Howell A, Dowsett M, Landberg G, TransATAC investigators Effects of cyclin D1 gene amplification and protein expression on time to recurrence in postmenopausal breast cancer patients treated with anastrozole or tamoxifen: a TransATAC study.. vol.14, (2) R57.
10.1186/bcr3161
Breast Cancer Res2012
Allawi Z, Cuzick J, Baum M, ATAC/LATTE investigators Does trauma or an intercurrent surgical intervention lead to a short-term increase in breast cancer recurrence rates?. vol.23, (4) 866 - 869.
10.1093/annonc/mdr316
Ann Oncol2012
Singh S, Cuzick J, Mesher D, Richmond B, Howell A Effect of baseline serum vitamin D levels on aromatase inhibitors induced musculoskeletal symptoms: results from the IBIS-II, chemoprevention study using anastrozole.. vol.132, (2) 625 - 629.
10.1007/s10549-011-1911-6
Breast Cancer Res Treat2012
Howell A, Astley S, Warwick J, Stavrinos P, Sahin S, Ingham S, McBurney H, Eckersley B, Harvie M, Wilson M, Beetles U, Warren R, Hufton A, Sergeant J, Newman W, Buchan I, Cuzick J, Evans DG Prevention of breast cancer in the context of a national breast screening programme.. vol.271, (4) 321 - 330.
10.1111/j.1365-2796.2012.02525.x
J Intern Med2012
Rae JM, Drury S, Hayes DF, Stearns V, Thibert JN, Haynes BP, Salter J, Sestak I, Cuzick J, Dowsett M, ATAC trialists CYP2D6 and UGT2B7 genotype and risk of recurrence in tamoxifen-treated breast cancer patients.. vol.104, (6) 452 - 460.
10.1093/jnci/djs126
J Natl Cancer Inst2012
Pinhel I, Hills M, Drury S, Salter J, Sumo G, A'Hern R, Bliss JM, Sestak I, Cuzick J, Barrett-Lee P, Harris A, Dowsett M, NCRI Adjuvant Breast Cancer Trial Management Group ER and HER2 expression are positively correlated in HER2 non-overexpressing breast cancer.. vol.14, (2) R46.
10.1186/bcr3145
Breast Cancer Res2012
Cuzick J, Berney DM, Fisher G, Mesher D, Møller H, Reid JE, Perry M, Park J, Younus A, Gutin A, Foster CS, Scardino P, Lanchbury JS, Stone S, Transatlantic Prostate Group Prognostic value of a cell cycle progression signature for prostate cancer death in a conservatively managed needle biopsy cohort.. vol.106, (6) 1095 - 1099.
10.1038/bjc.2012.39
Br J Cancer2012
Cuzick J The Role of HPV Testing in Cervical Screening. vol.226, () S2 - S2.JOURNAL OF PATHOLOGY2012
Albain K, Anderson S, Arriagada R, Barlow W, Bergh J, Bliss J, Buyse M, Cameron D, Carrasco E, Clarke M, Correa C, Coates A, Collins R, Costantino J, Cutter D, Cuzick J, Darby S, Davidson N, Davies C, Davies K Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100 000 women in 123 randomised trials. vol.379, (9814) 432 - 444.
10.1016/S0140-6736(11)61625-5
LANCET2012
Jeetle SS, Yang ZH, Stankiewicz E, Fisher G, Cooper C, Foster CS, Moller H, Scardino P, Reuter VE, Cuzick J, Berney D Androgen Receptor in Tumor and Stroma in Conservatively Treated Prostate Cancer. vol.92, () 215A - 215A.LABORATORY INVESTIGATION2012
Stone SM, Cuzick J, Reid JE, Mesher D, Berney DM, Moller H, Speights VO, Fisher G, Gutin A, Swanson GP, Lanchbury JS, Grp TP Cell cycle progression genes differentiate indolent from aggressive prostate cancer. vol.11, (1) E430 - U942.EUROPEAN UROLOGY SUPPLEMENTS2012
Berney D, Fisher G, Yang ZH, Moller H, Kudahetti S, Foster C, Reuter V, Scardino P, Cuzick J Molecular Factors Showing Multivariate Significance for Outcome in a Conservatively Treated Prostate Cancer Biopsy Cohort. vol.92, () 192A - 192A.LABORATORY INVESTIGATION2012
Armitage J, Cuzick J, Elwood P, Longley M, Perkins A, Spencer K, Turner H, Porch S, Lyness S, Kennedy J, Henderson G Aspirin for the older person: report of a meeting at the Royal Society of Medicine, London, 3rd November 2011.. vol.6, () 245.
10.3332/ecancer.2012.245
Ecancermedicalscience2012
Rijkaart DC, Berkhof J, Rozendaal L, van Kemenade FJ, Bulkmans NWJ, Heideman DAM, Kenter GG, Cuzick J, Snijders PJF, Meijer CJLM Human papillomavirus testing for the detection of high-grade cervical intraepithelial neoplasia and cancer: final results of the POBASCAM randomised controlled trial.. vol.13, (1) 78 - 88.
10.1016/S1470-2045(11)70296-0
Lancet Oncol2012
Cheol Kim D, Thorat MA, Lee MR, Cho SH, Vasiljevi¿ N, Scibior-Bentkowska D, Wu K, Ahmad AS, Duffy S, Cuzick JM, Lorincz AT Quantitative DNA methylation and recurrence of breast cancer: a study of 30 candidate genes.. vol.11, (2-3) 75 - 88.
10.3233/CBM-2012-0266
Cancer Biomark2012
Dowsett M, Lopez-Knowles E, Sidhu K, Pineda S, Cowens JW, Ferree S, Storhoff J, Schaper C, Cuzick J Comparison of PAM50 Risk of Recurrence (ROR) Score with OncotypeDx and IHC4 for Predicting Residual Risk of RFS and Distant-(D)RFS after Endocrine Therapy: A TransATAC Study.. vol.71, () .
10.1158/0008-5472.SABCS11-S4-5
CANCER RESEARCH2011
Rae JM, Sestak I, Henry NL, Drury S, Hayes DF, Thibert JN, Lopez-Knowles E, Salter J, Pineda S, Cuzick J, Dowsett M Correlation between Gene Variants in CYP19 (Aromatase) and TCL1A with Disease and Tolerability Endpoints in the ATAC Trial.. vol.71, () .
10.1158/0008-5472.SABCS11-P1-06-02
CANCER RESEARCH2011
Evans DGR, Astley S, Stavrinos P, Sahin S, Ingham S, McBurney H, Eckersley B, Wilson M, Beetles U, Harvie M, Warren R, Sergeant J, Hufton A, Warwick J, Newman W, Buchan I, Cuzick J, Howell A Feasibility and Acceptability of Offering Breast Cancer Risk Estimation in the Context of the UK National Health Service Breast Cancer Screening Programme: A New Paradigm for Cancer Prevention.. vol.71, () .
10.1158/0008-5472.SABCS11-P4-11-07
CANCER RESEARCH2011
Dowsett M, Afentakis M, Pineda S, Salter J, Howell A, Buzdar A, Forbes JF, Cuzick J Immunohistochemical (IHC) BAG1 Expression Improves the Estimation of Residual Risk (RR) by IHC4 in Postmenopausal Patients Treated with Anastrozole or Tamoxifen: A TransATAC Study.. vol.71, () .
10.1158/0008-5472.SABCS11-P2-02-01
CANCER RESEARCH2011
Sestak I, Cuzick J, Dowsett M, Salter J, Quinn E, Zabaglo L, Howell A, Buzdar A, Forbes J Prediction of Residual Risk of Recurrence after 5 Years of Follow-Up by Clinicopathologic Variables and 4 IHC Markers: A TransATAC Study.. vol.71, () .
10.1158/0008-5472.SABCS11-P2-12-09
CANCER RESEARCH2011
Assi V, Warwick J, Cuzick J, Duffy SW Clinical and epidemiological issues in mammographic density.. vol.9, (1) 33 - 40.
10.1038/nrclinonc.2011.173
Nat Rev Clin Oncol2011
Bissett SL, Howell-Jones R, Swift C, De Silva N, Biscornet L, Parry JV, Saunders NA, Nathan M, Soldan K, Szarewski A, Cuzick J, Beddows S Human papillomavirus genotype detection and viral load in paired genital and urine samples from both females and males (vol 83, pg 1744, 2011). vol.83, (12) 2237 - 2237.
10.1002/jmv.22250
J MED VIROL2011
Almonte M, Ferreccio C, Gonzales M, Delgado JM, Buckley CH, Luciani S, Robles SC, Winkler JL, Tsu VD, Jeronimo J, Cuzick J, Sasieni P Risk factors for high-risk human papillomavirus infection and cofactors for high-grade cervical disease in Peru.. vol.21, (9) 1654 - 1663.
10.1097/IGC.0b013e3182288104
Int J Gynecol Cancer2011
Tang G, Cuzick J, Costantino JP, Dowsett M, Forbes JF, Crager M, Mamounas EP, Shak S, Wolmark N Risk of recurrence and chemotherapy benefit for patients with node-negative, estrogen receptor-positive breast cancer: recurrence score alone and integrated with pathologic and clinical factors.. vol.29, (33) 4365 - 4372.
10.1200/JCO.2011.35.3714
J Clin Oncol2011
Dowsett M, Nielsen TO, A'Hern R, Bartlett J, Coombes RC, Cuzick J, Ellis M, Henry NL, Hugh JC, Lively T, McShane L, Paik S, Penault-Llorca F, Prudkin L, Regan M, Salter J, Sotiriou C, Smith IE, Viale G, Zujewski JA Assessment of Ki67 in breast cancer: recommendations from the International Ki67 in Breast Cancer working group.. vol.103, (22) 1656 - 1664.
10.1093/jnci/djr393
J Natl Cancer Inst2011
Ring A, Sestak I, Baum M, Howell A, Buzdar A, Dowsett M, Forbes JF, Cuzick J Influence of comorbidities and age on risk of death without recurrence: a retrospective analysis of the Arimidex, Tamoxifen Alone or in Combination trial.. vol.29, (32) 4266 - 4272.
10.1200/JCO.2011.35.5545
J Clin Oncol2011
Cuzick J, Dowsett M, Pineda S, Wale C, Salter J, Quinn E, Zabaglo L, Mallon E, Green AR, Ellis IO, Howell A, Buzdar AU, Forbes JF Prognostic value of a combined estrogen receptor, progesterone receptor, Ki-67, and human epidermal growth factor receptor 2 immunohistochemical score and comparison with the Genomic Health recurrence score in early breast cancer.. vol.29, (32) 4273 - 4278.
10.1200/JCO.2010.31.2835
J Clin Oncol2011
Bissett SL, Howell-Jones R, Swift C, De Silva N, Biscornet L, Parry JV, Saunders NA, Nathan M, Soldan K, Szarewski A, Cuzick J, Beddows S Human Papillomavirus Genotype Detection and Viral Load in Paired Genital and Urine Samples From Both Females and Males. vol.83, (10) 1744 - 1751.
10.1002/jmv.22167
J MED VIROL2011
Almonte M, Sasieni P, Cuzick J Incorporating human papillomavirus testing into cytological screening in the era of prophylactic vaccines.. vol.25, (5) 617 - 629.
10.1016/j.bpobgyn.2011.05.003
Best Pract Res Clin Obstet Gynaecol2011
Sestak I, Harvie M, Howell A, Forbes JF, Dowsett M, Cuzick JM Weight change associated with anastrozole and tamoxifen treatment in postmenopausal women with breast cancer or at high risk of developing it. vol.29, (27) .JOURNAL OF CLINICAL ONCOLOGY2011
Sestak I, Harvie M, Howell A, Forbes JF, Dowsett M, Cuzick JM Weight change associated with anastrozole and tamoxifen treatment in postmenopausal women with breast cancer or at high risk of developing it.. vol.29, (27_suppl) 165.J Clin Oncol2011
Cuzick J Cervix Cancer Vaccination. vol.47, () S15 - S15.EUROPEAN JOURNAL OF CANCER2011
Evans G, Astley S, Stavrinos P, Sahin S, Ingham S, McBurney H, Eckersley B, Harvie M, Wilson M, Beetles U, Warren R, Hufton A, Warwick J, Newman W, Buchan I, Cuzick J, Howell A Feasibility and acceptability of offering breast cancer risk estimation in the context of the UK National Health Service Breast Cancer Screening Programme: a new paradigm for cancer prevention. vol.48, () S41 - S41.JOURNAL OF MEDICAL GENETICS2011
Cuzick J, Glasier A, La Vecchia C, Maraganore DM, Negri E, Rossi M, Spector T, Trichopoulos D, van Baak MA, Zocchetti C, Baird DT, Benagiano G, Collins J, Crosignani PG, Diczfalusy E, Evers JLH, Gianaroli L, Volpe A, ESHRE Capri Workshop Grp Perimenopausal risk factors and future health. vol.17, (5) 706 - 717.
10.1093/humupd/dmr020
HUM REPROD UPDATE2011
Jeetle S, Yang ZH, Stankiewicz E, Fisher G, Cuzick J, Berney D Long-term outcome and neuroendocrine differentiation in conservatively treated prostate cancers. vol.459, () S59 - S59.VIRCHOWS ARCH2011
Dowsett M, Salter J, Zabaglo L, Mallon E, Howell A, Buzdar AU, Forbes J, Pineda S, Cuzick J Predictive algorithms for adjuvant therapy: TransATAC.. vol.76, (8) 777 - 780.
10.1016/j.steroids.2011.02.032
Steroids2011
Cuzick JM, Fisher G, Berney D, Mesher D, Moller H, Reid JE, Gutin A, Lanchbury JS, Stone S Prognostic value of a 46-gene cell cycle progression (CCP) RNA signature for prostate cancer death in a conservatively managed watchful waiting needle biopsy cohort. vol.29, (15) .JOURNAL OF CLINICAL ONCOLOGY2011
Cuzick JM, Fisher G, Berney D, Mesher D, Møller H, Reid JE, Gutin A, Lanchbury JS, Stone S Prognostic value of a 46-gene cell cycle progression (CCP) RNA signature for prostate cancer death in a conservatively managed watchful waiting needle biopsy cohort.. vol.29, (15_suppl) 4542.J Clin Oncol2011
O'Brien MF, Cronin AM, Fearn PA, Savage CJ, Smith B, Stasi J, Scardino PT, Fisher G, Cuzick J, Møller H, Oliver RT, Berney DM, Foster CS, Eastham JA, Vickers AJ, Lilja H, Trans-Atlantic Prostate Group Evaluation of prediagnostic prostate-specific antigen dynamics as predictors of death from prostate cancer in patients treated conservatively.. vol.128, (10) 2373 - 2381.
10.1002/ijc.25570
Int J Cancer2011
Cuzick J, Warwick J, Pinney E, Duffy SW, Cawthorn S, Howell A, Forbes JF, Warren RML Tamoxifen-induced reduction in mammographic density and breast cancer risk reduction: a nested case-control study.. vol.103, (9) 744 - 752.
10.1093/jnci/djr079
J Natl Cancer Inst2011
Cuzick J, DeCensi A, Arun B, Brown PH, Castiglione M, Dunn B, Forbes JF, Glaus A, Howell A, von Minckwitz G, Vogel V, Zwierzina H Preventive therapy for breast cancer: a consensus statement.. vol.12, (5) 496 - 503.
10.1016/S1470-2045(11)70030-4
Lancet Oncol2011
Harvie MN, Pegington M, Mattson MP, Frystyk J, Dillon B, Evans G, Cuzick J, Jebb SA, Martin B, Cutler RG, Son TG, Maudsley S, Carlson OD, Egan JM, Flyvbjerg A, Howell A The effects of intermittent or continuous energy restriction on weight loss and metabolic disease risk markers: a randomized trial in young overweight women.. vol.35, (5) 714 - 727.
10.1038/ijo.2010.171
Int J Obes (Lond)2011
Eastell R, Adams J, Clack G, Howell A, Cuzick J, Mackey J, Beckmann MW, Coleman RE Long-term effects of anastrozole on bone mineral density: 7-year results from the ATAC trial.. vol.22, (4) 857 - 862.
10.1093/annonc/mdq541
Ann Oncol2011
Stankiewicz E, Prowse DM, Ng M, Cuzick J, Mesher D, Hiscock F, Lu Y-J, Watkin N, Corbishley C, Lam W, Berney DM Alternative HER/PTEN/Akt pathway activation in HPV positive and negative penile carcinomas.. vol.6, (3) e17517.
10.1371/journal.pone.0017517
PLoS One2011
Cuzick J, Sestak I, Baum M, Buzdar A, Howell A, Dowsett M, Forbes JF, for the ATAC/LATTE investigators 10-year analysis of the ATAC trial: wrong conclusion? - Authors' reply.. vol.12, (3) 217.
10.1016/S1470-2045(11)70050-X
Lancet Oncol2011
Cuzick J, Sestak I, Baum M, Buzdar A, Howell A, Dowsett M, Forbes JF, ATAC LATTE Investigators 10-year analysis of the ATAC trial: wrong conclusion? Reply. vol.12, (3) 217 - 217.
10.1016/S1470-2045(11)70050-X
LANCET ONCOL2011
Cuzick J, Swanson GP, Fisher G, Brothman AR, Berney DM, Reid JE, Mesher D, Speights VO, Stankiewicz E, Foster CS, Møller H, Scardino P, Warren JD, Park J, Younus A, Flake DD, Wagner S, Gutin A, Lanchbury JS, Stone S Prognostic value of an RNA expression signature derived from cell cycle proliferation genes in patients with prostate cancer: a retrospective study.. vol.12, (3) 245 - 255.
10.1016/S1470-2045(10)70295-3
Lancet Oncol2011
Stankiewicz E, Mesher D, Ng M, Cuzick J, Prowse D, Hiscock F, Lu FJ, Lam W, Watkin N, Corbishley C, Berney DM Alternative Pathways of Akt Pathway Activation in HPV Positive and Negative Penile Carcinomas. vol.91, () 225A - 226A.LABORATORY INVESTIGATION2011
Stankiewicz E, Prowse DM, Ktori E, Cuzick J, Ambroisine L, Zhang X, Kudahetti S, Watkin N, Corbishley C, Berney DM The retinoblastoma protein/p16 INK4A pathway but not p53 is disrupted by human papillomavirus in penile squamous cell carcinoma.. vol.58, (3) 433 - 439.
10.1111/j.1365-2559.2011.03762.x
Histopathology2011
Vasiljevi¿ N, Wu K, Brentnall AR, Kim DC, Thorat MA, Kudahetti SC, Mao X, Xue L, Yu Y, Shaw GL, Beltran L, Lu Y-J, Berney DM, Cuzick J, Lorincz AT Absolute quantitation of DNA methylation of 28 candidate genes in prostate cancer using pyrosequencing.. vol.30, (4) 151 - 161.
10.3233/DMA-2011-0790
Dis Markers2011
Rajab R, Fisher G, Kattan MW, Foster CS, Møller H, Oliver T, Reuter V, Scardino PT, Cuzick J, Berney DM, Transatlantic Prostate Group An improved prognostic model for stage T1a and T1b prostate cancer by assessments of cancer extent.. vol.24, (1) 58 - 63.
10.1038/modpathol.2010.182
Mod Pathol2011
Cuzick J, Sestak I, Pinder SE, Ellis IO, Forsyth S, Bundred NJ, Forbes JF, Bishop H, Fentiman IS, George WD Effect of tamoxifen and radiotherapy in women with locally excised ductal carcinoma in situ: long-term results from the UK/ANZ DCIS trial.. vol.12, (1) 21 - 29.
10.1016/S1470-2045(10)70266-7
Lancet Oncol2011
Singh S, Cuzick J, Blake GM, Mesher D, Patel R, Truscott J, Coleman R, Howell A, Forbes J, Eastell R One year effect of anastrozole and risedronate on bone mineral density: First results from the IBIS-II bone sub-study. vol.48, (1) S24 - S24.
10.1016/j.bone.2010.10.064
BONE2011
Cuzick J Breast cancer prevention in the developing world.. vol.12 Suppl 4, () S9.
10.1186/bcr2738
Breast Cancer Res2010
Rae JM, Drury S, Hayes DF, Stearns V, Thibert JN, Haynes BP, Salter J, Pineda S, Cuzick J, Dowsett M Lack of Correlation between Gene Variants in Tamoxifen Metabolizing Enymes with Primary Endpoints in the ATAC Trial.. vol.70, () .
10.1158/0008-5472.SABCS10-S1-7
CANCER RESEARCH2010
Cuzick J, Sestak I, Baum M, Buzdar A, Howell A, Dowsett M, Forbes JF, ATAC LATTE Investigators Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial. vol.11, (12) 1135 - 1141.
10.1016/S1470-2045(10)70257-6
LANCET ONCOL2010
Cuzick J, Sestak I, Baum M, Buzdar A, Howell A, Dowsett M, Forbes JF, ATAC/LATTE investigators Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial.. vol.11, (12) 1135 - 1141.
10.1016/S1470-2045(10)70257-6
Lancet Oncol2010
Kerkhof M, Roobol MJ, Cuzick J, Sasieni P, Roemeling S, Schröder FH, Steyerberg EW Effect of the correction for noncompliance and contamination on the estimated reduction of metastatic prostate cancer within a randomized screening trial (ERSPC section Rotterdam).. vol.127, (11) 2639 - 2644.
10.1002/ijc.25278
Int J Cancer2010
Duffy SW, Mackay J, Thomas S, Anderson E, Evans DG, Fielder H, Fox R, Gray J, Gui G, Macmillan D, Moss S, Rogers C, Sainsbury R, Sibbering M, Boggis C, Burn J, Cuzick J, Haward B, Howell A, Mansel R Mammographic surveillance in women younger than 50 years who have a family history of breast cancer: tumour characteristics and projected effect on mortality in the prospective, single-arm, FH01 study. vol.11, (12) 1127 - 1134.
10.1016/S1470.2045(10)70263.1
LANCET ONCOL2010
Rajab R, Fisher G, Kattan MW, Foster CS, Oliver T, Møller H, Reuter V, Scardino P, Cuzick J, Berney DM, Transatlantic Prostate Group Measurements of cancer extent in a conservatively treated prostate cancer biopsy cohort.. vol.457, (5) 547 - 553.
10.1007/s00428-010-0971-z
Virchows Arch2010
Noon E, Singh S, Cuzick J, Spector TD, Williams FMK, Frost ML, Howell A, Harvie M, Eastell R, Coleman RE, Fogelman I, Blake GM, IBIS-II Bone Substudy Significant differences in UK and US female bone density reference ranges.. vol.21, (11) 1871 - 1880.
10.1007/s00198-009-1153-1
Osteoporos Int2010
Dowsett M, Pineda S, Cuzick J What Is the Value of the 21 Gene Recurrence Score in HER2-Negative Patients? Reply. vol.28, (31) E648 - E648.
10.1200/JCO.2010.31.2702
J CLIN ONCOL2010
Cuzick JM, Fisher G, Berney D, Mesher D, Moller H, Lanchbury J, Gutin A, Stone S PROGNOSTIC VALUE OF A CELL CYCLE EXPRESSION PROFILE SCORE AMONG MEN WITH CONSERVATIVELY TREATED LOCALIZED PROSTATE CANCER. vol.21, () 63 - 63.ANNALS OF ONCOLOGY2010
Sestak I, Distler W, Forbes JF, Dowsett M, Howell A, Cuzick J Effect of body mass index on recurrences in tamoxifen and anastrozole treated women: an exploratory analysis from the ATAC trial.. vol.28, (21) 3411 - 3415.
10.1200/JCO.2009.27.2021
J Clin Oncol2010
Cuzick J Tamoxifen and the factor V Leiden mutation.. vol.102, (13) 918 - 919.
10.1093/jnci/djq225
J Natl Cancer Inst2010
Cuzick J, Ambroisine L, Cadman L, Austin J, Ho L, Terry G, Liddle S, Dina R, McCarthy J, Buckley H, Bergeron C, Soutter WP, Lyons D, Szarewski A Performance of the Abbott RealTime High-Risk HPV Test in Women With Abnormal Cervical Cytology Smears. vol.82, (7) 1186 - 1191.
10.1002/jmv.21801
J MED VIROL2010
Pinder SE, Duggan C, Ellis IO, Cuzick J, Forbes JF, Bishop H, Fentiman IS, George WD, UK Coordinating Committee on Cancer Research (UKCCCR) Ductal Carcinoma In Situ (DCIS) Working Party A new pathological system for grading DCIS with improved prediction of local recurrence: results from the UKCCCR/ANZ DCIS trial.. vol.103, (1) 94 - 100.
10.1038/sj.bjc.6605718
Br J Cancer2010
Atkin WS, Cook CF, Cuzick J, Edwards R, Northover JMA, Wardle J, UK Flexible Sigmoidoscopy Screenin Single flexible sigmoidoscopy screening to prevent colorectal cancer: baseline findings of a UK multicentre randomised trial (vol 359, pg 1291, 2002). vol.375, (9732) 2142 - 2142.LANCET2010
Cuzick J Long-term follow-up in cancer prevention trials (It ain't over 'til it's over).. vol.3, (6) 689 - 691.
10.1158/1940-6207.CAPR-10-0096
Cancer Prev Res (Phila)2010
Shan L, Ambroisine L, Clark J, Yáñez-Muñoz RJ, Fisher G, Kudahetti SC, Yang J, Kia S, Mao X, Fletcher A, Flohr P, Edwards S, Attard G, De-Bono J, Young BD, Foster CS, Reuter V, Moller H, Oliver TD, Berney DM The identification of chromosomal translocation, t(4;6)(q22;q15), in prostate cancer.. vol.13, (2) 117 - 125.
10.1038/pcan.2010.2
Prostate Cancer Prostatic Dis2010
Tang G, Cuzick J, Wale C, Costantino JP, Crager M, Shak S, Wolmark N, Dowsett M, Forbes JF Recurrence risk of node-negative and ER-positive early-stage breast cancer patients by combining recurrence score, pathologic, and clinical information: A meta-analysis approach. vol.28, (15) .JOURNAL OF CLINICAL ONCOLOGY2010
Atkin WS, Edwards R, Kralj-Hans I, Wooldrage K, Hart AR, Northover JMA, Parkin DM, Wardle J, Duffy SW, Cuzick J, UK Flexible Sigmoidoscopy Trial Investigators Once-only flexible sigmoidoscopy screening in prevention of colorectal cancer: a multicentre randomised controlled trial.. vol.375, (9726) 1624 - 1633.
10.1016/S0140-6736(10)60551-X
Lancet2010
Cuzick J Long-term cervical cancer prevention strategies across the globe.. vol.117, (2 Suppl) S11 - S14.
10.1016/j.ygyno.2010.01.025
Gynecol Oncol2010
Yao S, Bee A, Brewer D, Dodson A, Beesley C, Ke Y, Ambroisine L, Fisher G, Møller H, Dickinson T, Gerard P, Lian L-Y, Risk J, Lane B, Smith P, Reuter V, Berney D, Gosden C, Scardino P, Cuzick J PRKC-ζ Expression Promotes the Aggressive Phenotype of Human Prostate Cancer Cells and Is a Novel Target for Therapeutic Intervention.. vol.1, (5) 444 - 464.
10.1177/1947601910376079
Genes Cancer2010
Mesher D, Szarewski A, Cadman L, Cubie H, Kitchener H, Luesley D, Menon U, Hulman G, Desai M, Ho L, Terry G, Williams A, Sasieni P, Cuzick J Long-term follow-up of cervical disease in women screened by cytology and HPV testing: results from the HART study.. vol.102, (9) 1405 - 1410.
10.1038/sj.bjc.6605619
Br J Cancer2010
Dowsett M, Cuzick J, Wale C, Forbes J, Mallon EA, Salter J, Quinn E, Dunbier A, Baum M, Buzdar A, Howell A, Bugarini R, Baehner FL, Shak S Prediction of risk of distant recurrence using the 21-gene recurrence score in node-negative and node-positive postmenopausal patients with breast cancer treated with anastrozole or tamoxifen: a TransATAC study.. vol.28, (11) 1829 - 1834.
10.1200/JCO.2009.24.4798
J Clin Oncol2010
Cuzick J, Castañón A, Sasieni P Predicted impact of vaccination against human papillomavirus 16/18 on cancer incidence and cervical abnormalities in women aged 20-29 in the UK.. vol.102, (5) 933 - 939.
10.1038/sj.bjc.6605528
Br J Cancer2010
Ronco G, Giorgi-Rossi P, Carozzi F, Confortini M, Dalla Palma P, Del Mistro A, Ghiringhello B, Girlando S, Gillio-Tos A, De Marco L, Naldoni C, Pierotti P, Rizzolo R, Schincaglia P, Zorzi M, Zappa M, Segnan N, Cuzick J, New Technologies for Cervical Cancer screening (NTCC) Working Group Efficacy of human papillomavirus testing for the detection of invasive cervical cancers and cervical intraepithelial neoplasia: a randomised controlled trial.. vol.11, (3) 249 - 257.
10.1016/S1470-2045(09)70360-2
Lancet Oncol2010
Reid AHM, Attard G, Ambroisine L, Fisher G, Kovacs G, Brewer D, Clark J, Flohr P, Edwards S, Berney DM, Foster CS, Fletcher A, Gerald WL, Møller H, Reuter VE, Scardino PT, Cuzick J, de Bono JS, Cooper CS, Transatlantic Prostate Group Molecular characterisation of ERG, ETV1 and PTEN gene loci identifies patients at low and high risk of death from prostate cancer.. vol.102, (4) 678 - 684.
10.1038/sj.bjc.6605554
Br J Cancer2010
Thomsen MK, Ambroisine L, Wynn S, Cheah KSE, Foster CS, Fisher G, Berney DM, Møller H, Reuter VE, Scardino P, Cuzick J, Ragavan N, Singh PB, Martin FL, Butler CM, Cooper CS, Swain A, Transatlantic Prostate Group SOX9 elevation in the prostate promotes proliferation and cooperates with PTEN loss to drive tumor formation.. vol.70, (3) 979 - 987.
10.1158/0008-5472.CAN-09-2370
Cancer Res2010
Stankiewicz E, Prowse DM, Cuzick J, Ambroisine L, Kudahetti S, Watkin N, Corbishley C, Berney DM The RB/p16 Pathway but Not p53 Is Disrupted by High Risk HPV in Penile Squamous Cell Carcinoma. vol.23, () 221A - 221A.MODERN PATHOLOGY2010
Dowsett M, Cuzick J, Ingle J, Coates A, Forbes J, Bliss J, Buyse M, Baum M, Buzdar A, Colleoni M, Coombes C, Snowdon C, Gnant M, Jakesz R, Kaufmann M, Boccardo F, Godwin J, Davies C, Peto R Meta-analysis of breast cancer outcomes in adjuvant trials of aromatase inhibitors versus tamoxifen.. vol.28, (3) 509 - 518.
10.1200/JCO.2009.23.1274
J Clin Oncol2010
Sasieni P, Castañón A, Cuzick J ACOG guidelines on cervical screening: a step in the right direction.. vol.17, (2) 55 - 56.
10.1258/jms.2010.010054
J Med Screen2010
Cuzick J Controversies in design and interpretation of adjuvant clinical trials.. vol.28 Suppl 1, () 28 - 34.
10.3109/07357907.2010.501633
Cancer Invest2010
Harvie M, Pegington M, Cuzick J, Frystyk J, Flyvbjerg A, Jebb S, Mattson M, Howell A Effect of intermittent versus continuous energy restriction on weight loss and breast cancer risk biomarkers. vol.12, () S9 - S10.
10.1186/bcr2525
BREAST CANCER RESEARCH2010
Kudahetti SC, Fisher G, Ambroisine L, Prowse D, Kattan MW, Foster CS, Møller H, Oliver T, Fletcher A, Cooper C, Reuter V, Scardino P, Cuzick J, Berney DM, Transatlantic Prostate Group Immunohistochemistry for p16, but not Rb or p21, is an independent predictor of prognosis in conservatively treated, clinically localised prostate cancer.. vol.42, (6) 519 - 523.
10.3109/00313025.2010.508788
Pathology2010
Distler W, Canzler U, Duffy SR, Howell A, Cuzick J, Baum M Undesirable Gynaecological and Operative Interventions during Treatment of Breast Cancer with Anastrozole and Tamoxifen. vol.70, (1) 57 - 61.
10.1055/s-0029-1240720
GEBURTSH FRAUENHEILK2010
Sasieni P, Castañon A, Cuzick J What is the right age for cervical cancer screening?. vol.6, (1) 1 - 4.
10.2217/whe.09.69
Womens Health (Lond)2010
Cuzick J Advances in Preventive Therapy.. vol.69, (24) 482S - 482S.CANCER RESEARCH2009
Cuzick J, Sestak I, Pinder SE, Ellis IO, Hackshaw A, Bundred NJ, Forbes JF, Bishop H, Fentiman IS, George WD Beneficial Effect of Tamoxifen for Women with DCIS: Long-Term Results front the UK/ANZ DCIS Trial in Women with Locally Excised DCIS. vol.69, (24) 493S - 493S.CANCER RESEARCH2009
Stone J, Warren RML, Pinney E, Warwick J, Cuzick J Determinants of percentage and area measures of mammographic density.. vol.170, (12) 1571 - 1578.
10.1093/aje/kwp313
Am J Epidemiol2009
Sestak I, Distler W, Forbes JF, Howell A, Cuzick J Effect of Body Mass Index on Recurrence in Hormone Receptor Positive Early Breast Cancer - A Retrospective Exploratory Analysis from the ATAC Trial. vol.69, (24) 553S - 553S.CANCER RESEARCH2009
Cuzick J, Dowsett M, Wale C, Salter J, Quinn E, Zabaglo L, Howell A, Buzdar A, Forbes JF Prognostic Value of a Combined ER, PgR, Ki67, HER2 Immunohistochemical (IHC4) Score and Comparison with the GHI Recurrence Score - Results from TransATAC.. vol.69, (24) 503S - 503S.CANCER RESEARCH2009
Cuzick J Use of Selective Estrogen Receptor Modulators in the Prevention of Breast Cancer: An Overview of the Randomized Trials. vol.69, (24) 532S - 532S.CANCER RESEARCH2009
Arbyn M, Ronco G, Cuzick J, Wentzensen N, Castle PE How to evaluate emerging technologies in cervical cancer screening?. vol.125, (11) 2489 - 2496.
10.1002/ijc.24774
Int J Cancer2009
Franceschi S, Cuzick J, Herrero R, Dillner J, Wheeler CM EUROGIN 2008 roadmap on cervical cancer prevention.. vol.125, (10) 2246 - 2255.
10.1002/ijc.24634
Int J Cancer2009
Sestak I, Sapunar F, Cuzick J Aromatase inhibitor-induced carpal tunnel syndrome: results from the ATAC trial.. vol.27, (30) 4961 - 4965.
10.1200/JCO.2009.22.0236
J Clin Oncol2009
Foster CS, Dodson AR, Ambroisine L, Fisher G, Møller H, Clark J, Attard G, De-Bono J, Scardino P, Reuter VE, Cooper CS, Berney DM, Cuzick J Hsp-27 expression at diagnosis predicts poor clinical outcome in prostate cancer independent of ETS-gene rearrangement.. vol.101, (7) 1137 - 1144.
10.1038/sj.bjc.6605227
Br J Cancer2009
Roobol MJ, Kerkhof M, Schröder FH, Cuzick J, Sasieni P, Hakama M, Stenman UH, Ciatto S, Nelen V, Kwiatkowski M, Lujan M, Lilja H, Zappa M, Denis L, Recker F, Berenguer A, Ruutu M, Kujala P, Bangma CH, Aus G Prostate cancer mortality reduction by prostate-specific antigen-based screening adjusted for nonattendance and contamination in the European Randomised Study of Screening for Prostate Cancer (ERSPC).. vol.56, (4) 584 - 591.
10.1016/j.eururo.2009.07.018
Eur Urol2009
Sasieni P, Castle PE, Cuzick J Further analysis of the ARTISTIC trial.. vol.10, (9) 841 - 842.
10.1016/S1470-2045(09)70246-3
Lancet Oncol2009
Stankiewicz E, Kudahetti SC, Prowse DM, Ktori E, Cuzick J, Ambroisine L, Zhang X, Watkin N, Corbishley C, Berney DM HPV infection and immunochemical detection of cell-cycle markers in verrucous carcinoma of the penis.. vol.22, (9) 1160 - 1168.
10.1038/modpathol.2009.77
Mod Pathol2009
Chlebowski R, Cuzick J, Amakye D, Bauerfeind I, Buzdar A, Chia S, Cutuli B, Linforth R, Maass N, Noguchi S, Robidoux A, Verma S, Hadji P Clinical perspectives on the utility of aromatase inhibitors for the adjuvant treatment of breast cancer.. vol.18 Suppl 2, () S1 - 11.
10.1016/S0960-9776(09)70002-5
Breast2009
Sasieni P, Castanon A, Cuzick J Screening and adenocarcinoma of the cervix. vol.125, (3) 525 - 529.
10.1002/ijc.24410
INT J CANCER2009
Sasieni P, Castanon A, Cuzick J Effectiveness of cervical screening with age: population based case-control study of prospectively recorded data.. vol.339, () b2968.
10.1136/bmj.b2968
BMJ2009
Visvanathan K, Chlebowski RT, Hurley P, Col NF, Ropka M, Collyar D, Morrow M, Runowicz C, Pritchard KI, Hagerty K, Arun B, Garber J, Vogel VG, Wade JL, Brown P, Cuzick J, Kramer BS, Lippman SM, American Society of Clinical Oncology American society of clinical oncology clinical practice guideline update on the use of pharmacologic interventions including tamoxifen, raloxifene, and aromatase inhibition for breast cancer risk reduction.. vol.27, (19) 3235 - 3258.
10.1200/JCO.2008.20.5179
J Clin Oncol2009
Kudahetti S, Fisher G, Ambroisine L, Foster C, Reuter V, Eastham J, Møller H, Kattan MW, Cooper CS, Scardino P, Cuzick J, Berney DM p53 immunochemistry is an independent prognostic marker for outcome in conservatively treated prostate cancer.. vol.104, (1) 20 - 24.
10.1111/j.1464-410X.2009.08407.x
BJU Int2009
Arbyn M, Cuzick J International agreement to join forces in synthesizing evidence on new methods for cervical cancer prevention.. vol.278, (1) 1 - 2.
10.1016/j.canlet.2008.09.002
Cancer Lett2009
Cuzick J, Otto F, Baron JA, Brown PH, Burn J, Greenwald P, Jankowski J, La Vecchia C, Meyskens F, Senn HJ, Thun M Aspirin and non-steroidal anti-inflammatory drugs for cancer prevention: an international consensus statement.. vol.10, (5) 501 - 507.
10.1016/S1470-2045(09)70035-X
Lancet Oncol2009
Kerkhot M, Roobol MJ, Steyerberg EW, Cuzick J, Schroder FH SECONDARY ANALYSIS OF THE EUROPEAN RANDOMIZED STUDY OF SCREENING FOR PROSTATE CANCER (ERSPC) - EFFECT OF PROSTATE CANCER SCREENING ON THE DEVELOPMENT OF METASTASES AFTER ADJUSTMENT FOR NON-COMPLIANCE AND CONTAMINATION. vol.181, (4) 233 - 233.JOURNAL OF UROLOGY2009
Berney DM, Gopalan A, Kudahetti S, Fisher G, Ambroisine L, Foster CS, Reuter V, Eastham J, Moller H, Kattan MW, Gerald W, Cooper C, Scardino P, Cuzick J Ki-67 and outcome in clinically localised prostate cancer: analysis of conservatively treated prostate cancer patients from the Trans-Atlantic Prostate Group study.. vol.100, (6) 888 - 893.
10.1038/sj.bjc.6604951
Br J Cancer2009
Cummings SR, Tice JA, Bauer S, Browner WS, Cuzick J, Ziv E, Vogel V, Shepherd J, Vachon C, Smith-Bindman R, Kerlikowske K Prevention of breast cancer in postmenopausal women: approaches to estimating and reducing risk.. vol.101, (6) 384 - 398.
10.1093/jnci/djp018
J Natl Cancer Inst2009
Howell A, ForbeS J, Cuzick J, ATAC Investigators Initial adjuvant therapy with anastrozole - early- and late-event data from the arimidex, tamoxifen, alone or in combination (ATAC) trial in the hormone-responsive population. vol.18, () S51 - S51.BREAST2009
Meijer CJLM, Berkhof J, Castle PE, Hesselink AT, Franco EL, Ronco G, Arbyn M, Bosch FX, Cuzick J, Dillner J, Heideman DAM, Snijders PJF Guidelines for human papillomavirus DNA test requirements for primary cervical cancer screening in women 30 years and older.. vol.124, (3) 516 - 520.
10.1002/ijc.24010
Int J Cancer2009
Ingle JN, Dowsett M, Cuzick J, Davies C Aromatase inhibitors versus tarnoxifen as adjuvant therapy for postmenopausal women with estrogen receptor positive breast cancer: meta-analyses of randomized trials of monotherapy and switching strategies. vol.69, (2) 66S - 66S.CANCER RESEARCH2009
Cuzick J, Warwick J, Pinney L, Warren R, Cawthorn S, Howell A, Duffy S Change in breast density as a biomarker of breast cancer risk reduction; results from IBIS-1.. vol.69, (2) 77S - 78S.CANCER RESEARCH2009
Sestak I, Cuzick J Characteristics of carpal-tunnel syndrome in the ATAC trial.. vol.69, (2) 326S - 326S.CANCER RESEARCH2009
Dowsett M, Cuzick J, Wales C, Forbes J, Mallon L, Salter J, Quinn E, Bugarini R, Baehner FL, Shak S, ATAC Trialisists Grp Risk of distant recurrence using oncotype DX in postmenopausal primary breast cancer patients treated with anastrozole or tamoxifen: a TransATAC study. vol.69, (2) 75S - 76S.CANCER RESEARCH2009
Harvie M, Chapman M, Cuzick J, Flyvbjerg A, Jebb S, Mattson M, Howell A The effect of intermittent versus continuous energy restriction on biomarkers of breast cancer. vol.69, (2) 95S - 96S.CANCER RESEARCH2009
Duffy SR, Distler W, Howell A, Cuzick J, Baum M A lower incidence of gynecologic adverse events and interventions with anastrozole than with tamoxifen in the ATAC trial.. vol.200, (1) 80.e1 - 80.e7.
10.1016/j.ajog.2008.07.062
Am J Obstet Gynecol2009
Oliver T, Lorinez A, Cuzick J Prostate cancer prevention by short-term anti-androgens: the rationale behind design of pilot studies.. vol.181, () 195 - 205.Recent Results Cancer Res2009
Howell A, Cuzick J Risk factors. Introduction to Session 1.. vol.11 Suppl 3, () S2.
10.1186/bcr2421
Breast Cancer Res2009
Rajab R, Fisher G, Ambroisine L, Foster CS, Moller H, Kattan M, Reuter V, Scardino P, Cuzick J, Berney DM The Predictive Power of Prostate Cancer Extent Measurements in a Large Watchful Waiting Cohort. vol.22, () 190A - 190A.MODERN PATHOLOGY2009
Cuzick J, Sestak I, Cella D, Fallowfield L, ATAC Trialists' Group Treatment-emergent endocrine symptoms and the risk of breast cancer recurrence: a retrospective analysis of the ATAC trial.. vol.9, (12) 1143 - 1148.
10.1016/S1470-2045(08)70259-6
Lancet Oncol2008
Sherrill B, Amonkar M, Wu Y, Hirst C, Stein S, Walker M, Cuzick J Relationship between effects on time-to-disease progression and overall survival in studies of metastatic breast cancer. vol.99, (10) 1572 - 1578.
10.1038/sj.bjc.6604759
BRIT J CANCER2008
Szarewski A, Ambroisine L, Cadman L, Austin J, Ho L, Terry G, Liddle S, Dina R, McCarthy J, Buckley H, Bergeron C, Soutter P, Lyons D, Cuzick J Comparison of predictors for high-grade cervical intraepithelial neoplasia in women with abnormal smears.. vol.17, (11) 3033 - 3042.
10.1158/1055-9965.EPI-08-0508
Cancer Epidemiol Biomarkers Prev2008
Clark J, Attard G, Ambroisine L, Mills IG, Fisher G, Flohr P, Reid A, Edwards S, Kovacs G, Berney D, Foster C, Massie CE, Fletcher A, De Bono JS, Scardino P, Cuzick J, Cooper CS, Transatlantic-Prostate-Grp ETS GENE TRANSLOCATIONS AND PROSTATE CANCER PROGNOSIS. vol.28, (6B) 4155 - 4156.ANTICANCER RES2008
Cuzick J Hormone replacement therapy and the risk of breast cancer.. vol.44, (16) 2344 - 2349.
10.1016/j.ejca.2008.07.041
Eur J Cancer2008
Dillner J, Rebolj M, Birembaut P, Petry KU, Szarewski A, Munk C, De Sanjose S, Naucler P, Lloveras B, Kjaer S, Cuzick J, Van Ballegooijen M, Clavel C, Iftner T Long term predictive values of cytology and human papillomavirus testing in cervical cancer screening: Joint European cohort study. vol.337, (7676) 969 - 972.
10.1136/bmj.a1662
BMJ2008
Dillner J, Rebolj M, Birembaut P, Petry K-U, Szarewski A, Munk C, de Sanjose S, Naucler P, Lloveras B, Kjaer S, Cuzick J, van Ballegooijen M, Clavel C, Iftner T, Joint European Cohort Study Long term predictive values of cytology and human papillomavirus testing in cervical cancer screening: joint European cohort study.. vol.337, () a1754.
10.1136/bmj.a1754
BMJ2008
Kudahetti S, Fisher G, Ambroidine I, Kattan M, Foster C, Oliver T, Moller H, Reuter V, Fearn P, Eastham J, Scardino P, Cuzick J, Berney D Cell-cycle proteins as biomarkers in clinically localised prostate cancer patients managed conservatively-results from the trans-atlantic prostate group. vol.53, () 279 - 280.HISTOPATHOLOGY2008
Jenkins VA, Ambroisine LM, Atkins L, Cuzick J, Howell A, Fallowfield LJ Effects of anastrozole on cognitive performance in postmenopausal women: a randomised, double-blind chemoprevention trial (IBIS II).. vol.9, (10) 953 - 961.
10.1016/S1470-2045(08)70207-9
Lancet Oncol2008
Carozzi F, Confortini M, Dalla Palma P, Del Mistro A, Gillio-Tos A, De Marco L, Giorgi-Rossi P, Pontenani G, Rosso S, Sani C, Sintoni C, Segnan N, Zorzi M, Cuzick J, Rizzolo R, Ronco G, New Technologies for Cervival Cancer Screening (NTCC) Working Group Use of p16-INK4A overexpression to increase the specificity of human papillomavirus testing: a nested substudy of the NTCC randomised controlled trial.. vol.9, (10) 937 - 945.
10.1016/S1470-2045(08)70208-0
Lancet Oncol2008
Oliver T, Lorincz A, Cuzick J CHEMO-PREVENTION OF: PROSTATE CANCER: THE RATIONALE BEHIND DESIGN OF PILOT STUDIES. vol.28, (5C) 3428 - 3429.ANTICANCER RES2008
Cuzick JM DETERMINING THE OPTIMAL TIMING AND DURATION OF THE USE OF AN AROMATASE INHIBITOR (AI) IN THE ADJUVANT TREATMENT OF POSTMENOPAUSAL HORMONE RECEPTOR-POSITIVE (HR plus ) BREAST CANCER (BC) USING MODELLING ANALYSES. vol.19, () 87 - 87.ANNALS OF ONCOLOGY2008
Cuzick J IBIS II: a breast cancer prevention trial in postmenopausal women using the aromatase inhibitor anastrozole.. vol.8, (9) 1377 - 1385.
10.1586/14737140.8.9.1377
Expert Rev Anticancer Ther2008
Sestak I, Cuzick J, Sapunar F, Eastell R, Forbes JF, Bianco AR, Buzdar AU, ATAC Trialists' Group Risk factors for joint symptoms in patients enrolled in the ATAC trial: a retrospective, exploratory analysis.. vol.9, (9) 866 - 872.
10.1016/S1470-2045(08)70182-7
Lancet Oncol2008
Cuzick J, Arbyn M, Sankaranarayanan R, Tsu V, Ronco G, Mayrand M-H, Dillner J, Meijer CJLM Overview of human papillomavirus-based and other novel options for cervical cancer screening in developed and developing countries.. vol.26 Suppl 10, () K29 - K41.
10.1016/j.vaccine.2008.06.019
Vaccine2008
Garland SM, Cuzick J, Domingo EJ, Goldie SJ, Kim Y-T, Konno R, Parkin DM, Qiao Y-L, Sankaranarayanan R, Stern PL, Tay SK, Bosch FX Recommendations for cervical cancer prevention in Asia Pacific.. vol.26 Suppl 12, () M89 - M98.
10.1016/j.vaccine.2008.06.020
Vaccine2008
Cuzick J Use of LHRH-agonists as adjuvant therapy for breast cancer.. vol.12, (8) 1065 - 1071.
10.1517/14728222.12.8.1065
Expert Opin Ther Targets2008
Attard G, Clark J, Ambroisine L, Mills IG, Fisher G, Flohr P, Reid A, Edwards S, Kovacs G, Berney D, Foster C, Massie CE, Fletcher A, De Bono JS, Scardino P, Cuzick J, Cooper CS, Transatlantic Prostate Group Heterogeneity and clinical significance of ETV1 translocations in human prostate cancer.. vol.99, (2) 314 - 320.
10.1038/sj.bjc.6604472
Br J Cancer2008
Cuzick J Primary endpoints for randomised trials of cancer therapy.. vol.371, (9631) 2156 - 2158.
10.1016/S0140-6736(08)60933-2
Lancet2008
Forbes JF, Cuzick J, Buzdar A, Howell A, Baum M, ATAC Trialists Grp ATAC: 100 month median follow-up (FU) shows continued superior efficacy and no excess fracture risk for anastrozole (A) compared with tamoxifen (T) after treatment completion. vol.109, (3) 590 - 590.BREAST CANCER RESEARCH AND TREATMENT2008
Buzdar AU, Cuzick J Is overall survival an appropriate endpoint in early breast cancer studies? Data from the ATAC study at 100-month median follow-up. vol.26, (15) .JOURNAL OF CLINICAL ONCOLOGY2008
Grimison PS, Coates AS, Forbes JF, Cuzick J, Furnival C, Craft PS, Snyder RD, Thornton RM, Lindsay DF, Simes RJ, Canc ANZB Tamoxifen (TAM) for the prevention of breast cancer: Importance of specific aspects of health-related quality of life (HRQL) to global health status in the ANZ BCTG substudy of IBIS-1 (ANZ 92P1). vol.26, (15) .JOURNAL OF CLINICAL ONCOLOGY2008
Cuzick J, Szarewski A, Mesher D, Cadman L, Austin J, Perryman K, Ho L, Terry G, Sasieni P, Dina R, Soutter WP Long-term follow-up of cervical abnormalities among women screened by HPV testing and cytology-Results from the Hammersmith study.. vol.122, (10) 2294 - 2300.
10.1002/ijc.23339
Int J Cancer2008
Cuzick J Review of Swedish cervical cancer screening program demonstrates effectiveness and room for improvement. vol.100, (9) 602 - 602.J NATL CANCER I2008
Cuzick J Routine audit of large-scale cervical cancer screening programs.. vol.100, (9) 605 - 606.
10.1093/jnci/djn131
J Natl Cancer Inst2008
Ronco G, Giorgi-Rossi P, Carozzi F, Confortini M, Dalla Palma P, Del Mistro A, Gillio-Tos A, Minucci D, Naldoni C, Rizzolo R, Schincaglia P, Volante R, Zappa M, Zorzi M, Cuzick J, Segnan N, New Technologies for Cervical Cancer Screening Working Group Results at recruitment from a randomized controlled trial comparing human papillomavirus testing alone with conventional cytology as the primary cervical cancer screening test.. vol.100, (7) 492 - 501.
10.1093/jnci/djn065
J Natl Cancer Inst2008
Cuzick J Aromatase inhibitors in early breast-cancer treatment: The story so far.. vol.17 Suppl 3, () S2 - S8.
10.1016/j.breast.2007.12.002
Breast2008
Sherrill B, Amonkar M, Wu Y, Hirst C, Stein S, Walkers M, Cuzick J Disease progression as a predictor of overall survival in metastatic breast cancer: a meta-analysis. vol.6, (7) 216 - 216.
10.1016/S1359-6349(08)70880-2
EJC SUPPLEMENTS2008
Cuzick J Optimal timing and duration of the use of an aromatase inhibitor (AI) in the adjuvant treatment of postmenopausal hormone receptor-positive (HR+) breast cancer (BC). vol.6, (7) 121 - 121.
10.1016/S1359-6349(08)70562-7
EJC SUPPLEMENTS2008
Sestak I, Forbes JF, Edwards R, Howell A, Cuzick J Timing and severity of prominent side effects of anastrozole and tamoxifen. vol.6, (7) 71 - 71.
10.1016/S1359-6349(08)70389-6
EJC SUPPLEMENTS2008
Clark J, Attard G, Jhavar S, Flohr P, Reid A, De-Bono J, Eeles R, Scardino P, Cuzick J, Fisher G, Parker MD, Foster CS, Berney D, Kovacs G, Cooper CS Complex patterns of ETS gene alteration arise during cancer development in the human prostate.. vol.27, (14) 1993 - 2003.
10.1038/sj.onc.1210843
Oncogene2008
Franco EL, Cuzick J Cervical cancer screening following prophylactic human papillomavirus vaccination.. vol.26 Suppl 1, () A16 - A23.
10.1016/j.vaccine.2007.11.069
Vaccine2008
Eastell R, Adams JE, Coleman RE, Howell A, Hannon RA, Cuzick J, Mackey JR, Beckmann MW, Clack G Effect of anastrozole on bone mineral density: 5-year results from the anastrozole, tamoxifen, alone or in combination trial 18233230.. vol.26, (7) 1051 - 1057.
10.1200/JCO.2007.11.0726
J Clin Oncol2008
Oliver RTD, Lorincz A, Cuzick J Prostate cancer prevention by short-term antiandrogens: A novel strategy. vol.6, (3) 32 - 32.
10.1016/S1359-6349(08)70224-6
EJC SUPPLEMENTS2008
Dowsett M, Allred C, Knox J, Quinn E, Salter J, Wale C, Cuzick J, Houghton J, Williams N, Mallon E, Bishop H, Ellis I, Larsimont D, Sasano H, Carder P, Cussac AL, Knox F, Speirs V, Forbes J, Buzdar A Relationship between quantitative estrogen and progesterone receptor expression and human epidermal growth factor receptor 2 (HER-2) status with recurrence in the Arimidex, Tamoxifen, Alone or in Combination trial.. vol.26, (7) 1059 - 1065.
10.1200/JCO.2007.12.9437
J Clin Oncol2008
Cuzick J Use of aromatase inhibitors in breast cancer prevention. vol.6, (3) 21 - 21.
10.1016/S1359-6349(08)70213-1
EJC SUPPLEMENTS2008
Eastham JA, Kattan MW, Fearn P, Fisher G, Berney DM, Oliver T, Foster CS, Moller H, Reuter V, Cuzick J, Scardino P, Transatlantic Prostate Grp Local progression among men with conservatively treated localized prostate cancer: Results from the transatlantic prostate group. vol.53, (2) 347 - 354.
10.1016/j.eururo.2007.05.015
EUR UROL2008
Attard G, Clark J, Ambroisine L, Fisher G, Kovacs G, Flohr P, Berney D, Foster CS, Fletcher A, Gerald WL, Moller H, Reuter V, De Bono JS, Scardino P, Cuzick J, Cooper CS, Transatlantic Prostate Group Duplication of the fusion of TMPRSS2 to ERG sequences identifies fatal human prostate cancer.. vol.27, (3) 253 - 263.
10.1038/sj.onc.1210640
Oncogene2008
Cuzick J Assessing risk for breast cancer.. vol.10 Suppl 4, () S13.
10.1186/bcr2173
Breast Cancer Res2008
Cuzick J Chemoprevention of breast cancer.. vol.15, (1) 10 - 16.
10.1007/s12282-007-0006-z
Breast Cancer2008
Arimidex, Tamoxifen, Alone or in Combination (ATAC) Trialists' Group , Forbes JF, Cuzick J, Buzdar A, Howell A, Tobias JS, Baum M Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial.. vol.9, (1) 45 - 53.
10.1016/S1470-2045(07)70385-6
Lancet Oncol2008
Singh S, Cuzick J, Ferguson S, Blake G, Truscott J, Coleman R, Eastel R, Howell A Effect of anastrozole on bone mineral density after one year of treatment: Results from bone sub-study of the International Breast Cancer Prevention Study (IBIS-II). vol.34, () S53 - S54.
10.1016/j.ctrv.2008.03.037
CANCER TREATMENT REVIEWS2008
Eastell R, Adams JE, Clack G, Howell A, Hannon RA, Cuzick J, Mackey JR, Beckmann M, Coleman R Effect of stopping anastrozole on bone mineral density: Seven-year results from the ATAC trial. vol.82, () S84 - S84.CALCIFIED TISSUE INT2008
Berney DM, Gopalan A, Kudahetti S, Ambroisine L, Fisher G, Kattan M, Moller H, Foster C, Reuter V, Cuzick J, Scardino P, Cooper C, Gerald W KI-67 is an independent predictor of outcome in conservatively treated clinically localised prostate cancer. vol.88, () 148A - 148A.LABORATORY INVESTIGATION2008
Berney DM, Gopalan A, Kudahetti S, Ambroisine L, Fisher G, Kattan M, Moller H, Foster C, Reuter V, Cuzick J, Scardino P, Cooper C, Gerald W Ki-67 is an independent predictor of outcome in conservatively treated clinically localised prostate cancer. vol.21, () 148A - 148A.MODERN PATHOLOGY2008
Kattan MW, Cuzick J, Fisher G, Berney DM, Oliver T, Foster CS, Moller H, Reuter V, Fearn P, Eastham J, Scardino PT, Transatlantic Prostate Grp Nomogram incorporating PSA level to predict cancer-specific survival for men with clinically localized prostate cancer managed without curative intent. vol.112, (1) 69 - 74.
10.1002/cncr.23106
CANCER2008
Howell A, Bundred NJ, Cuzick J, Allred DC, Clarke R Response and resistance to the endocrine prevention of breast cancer.. vol.617, () 201 - 211.
10.1007/978-0-387-69080-3_19
Adv Exp Med Biol2008
Harvie M, Chapman M, Cuzick J, Flyvbjerg A, Hopwood P, Jebb S, Parfitt G, Howell A The effect of intermittent versus chronic energy restriction on breast cancer risk biomarkers in premenopausal women: a randomised pilot trial. vol.10, () S27 - S28.
10.1186/bcr1937
BREAST CANCER RESEARCH2008
Duffy SW, Nagtegaal ID, Astley SM, Gillan MGC, McGee MA, Boggis CRM, Wilson M, Beetles UM, Griffiths MA, Jain AK, Johnson J, Roberts R, Deans H, Duncan KA, Iyengar G, Griffiths PM, Warwick J, Cuzick J, Gilbert FJ Visually assessed breast density, breast cancer risk and the importance of the craniocaudal view.. vol.10, (4) R64.
10.1186/bcr2123
Breast Cancer Res2008
Giorgi-Rossi P, Segnan N, Zappa M, Naldoni C, Zorzi M, Confortini M, Merito M, Cuzick J, Ronco G, NTCC Working Group The impact of new technologies in cervical cancer screening: results of the recruitment phase of a large randomised controlled trial from a public health perspective.. vol.121, (12) 2729 - 2734.
10.1002/ijc.23055
Int J Cancer2007
Forbes JF, Cuzick J, Buzdar A, Howell A, Baum M, ATAC Trialists Grp ATAC: 100 month median follow-up (FU) shows continued superior efficacy and no excess fracture risk for anastrozole (A) compared with tamoxifen (T) after treatment completion. vol.106, () S12 - S13.BREAST CANCER RESEARCH AND TREATMENT2007
Singh S, Cuzick J, Edwards R, Blake G, Truscott J, Coleman R, Eastell R, Howell A Effect of anastrozole on bone mineral density after one year of treatment: results from bone sub-study of the International Breast Cancer Intervention Study (IBIS-II). vol.106, () S9 - S9.BREAST CANCER RESEARCH AND TREATMENT2007
Cuzick J Hormone replacement therapy and breast cancer - a summary of results from other studies. vol.106, () S3 - S3.BREAST CANCER RESEARCH AND TREATMENT2007
Cuzick J Hot flushes and the risk of recurrence - retrospective, exploratory results from the ATAC trial. vol.106, () S108 - S108.BREAST CANCER RESEARCH AND TREATMENT2007
Berney DM, Fisher G, Kattan MW, Oliver RTD, Møller H, Fearn P, Eastham J, Scardino P, Cuzick J, Reuter VE, Foster CS, Trans-Atlantic Prostate Group Major shifts in the treatment and prognosis of prostate cancer due to changes in pathological diagnosis and grading.. vol.100, (6) 1240 - 1244.
10.1111/j.1464-410X.2007.07199.x
BJU Int2007
Eastell R, Coleman R, Mansel R, Bianco A, Nagykalnai T, Cuzick J, ATAC Trialists Grp The effect of anastrozole on bone mineral density: updated results from the bone subprotocol of the ATAC trial. vol.106, () S109 - S109.BREAST CANCER RESEARCH AND TREATMENT2007
Berney DM, Fisher G, Kattan MW, Oliver RTD, Møller H, Fearn P, Eastham J, Scardino P, Cuzick J, Reuter VE, Foster CS, Trans-Atlantic prostate group Pitfalls in the diagnosis of prostatic cancer: retrospective review of 1791 cases with clinical outcome.. vol.51, (4) 452 - 457.
10.1111/j.1365-2559.2007.02819.x
Histopathology2007
Ronco G, Brezzi S, Carozzi F, Dalla Palma P, Giorgi-Rossi P, Minucci D, Naldoni C, Segnan N, Zappa M, Zorzi M, Cuzick J, NTCC study group The New Technologies for Cervical Cancer Screening randomised controlled trial. An overview of results during the first phase of recruitment.. vol.107, (1 Suppl 1) S230 - S232.
10.1016/j.ygyno.2007.07.021
Gynecol Oncol2007
Cuzick J Adjusting for non-compliance and contamination in randomised clinical trials (vol 16, pg 1017, 1997). vol.26, (20) 3821 - 3821.
10.1002/sim.2922
STAT MED2007
Sestak I, Edwards R, Howell A, Cuzick J Effect of tamoxifen on serum lipid levels in women at increased risk of breast cancer. vol.5, (3) 31 - 31.
10.1016/S1359-6349(07)71791-3
EJC SUPPLEMENTS2007
Almonte M, Ferreccio C, Winkler JL, Cuzick J, Tsu V, Robles S, Takahashi R, Sasieni P Cervical screening by visual inspection, HPV testing, liquid-based and conventional cytology in Amazonian Peru.. vol.121, (4) 796 - 802.
10.1002/ijc.22757
Int J Cancer2007
Cuzick J The ATAC trial: the vanguard trial for use of aromatase inhibitors in early breast cancer.. vol.7, (8) 1089 - 1094.
10.1586/14737140.7.8.1089
Expert Rev Anticancer Ther2007
Ronco G, Cuzick J, Pierotti P, Cariaggi MP, Dalla Palma P, Naldoni C, Ghiringhello B, Giorgi-Rossi P, Minucci D, Parisio F, Pojer A, Schiboni ML, Sintoni C, Zorzi M, Segnan N, Confortini M Accuracy of liquid based versus conventional cytology: overall results of new technologies for cervical cancer screening: randomised controlled trial.. vol.335, (7609) 28.
10.1136/bmj.39196.740995.BE
BMJ2007
Roemeling S, Roobol MJ, Otto SJ, Habbema DF, Gosselaar C, Lous JJ, Cuzick J, Schröder FH Feasibility study of adjustment for contamination and non-compliance in a prostate cancer screening trial.. vol.67, (10) 1053 - 1060.
10.1002/pros.20606
Prostate2007
Santen RJ, Boyd NF, Chlebowski RT, Cummings S, Cuzick J, Dowsett M, Easton D, Forbes JF, Key T, Hankinson SE, Howell A, Ingle J, Breast Cancer Prevention Collaborative Group Critical assessment of new risk factors for breast cancer: considerations for development of an improved risk prediction model.. vol.14, (2) 169 - 187.
10.1677/ERC-06-0045
Endocr Relat Cancer2007
LHRH-agonists in Early Breast Cancer Overview group , Cuzick J, Ambroisine L, Davidson N, Jakesz R, Kaufmann M, Regan M, Sainsbury R Use of luteinising-hormone-releasing hormone agonists as adjuvant treatment in premenopausal patients with hormone-receptor-positive breast cancer: a meta-analysis of individual patient data from randomised adjuvant trials.. vol.369, (9574) 1711 - 1723.
10.1016/S0140-6736(07)60778-8
Lancet2007
Cuzick J Mammographic breast density.. vol.356, (18) 1885 - 1887.
10.1056/NEJMc070404
N Engl J Med2007
Shaw GL, Wilson P, Cuzick J, Prowse DM, Goldenberg SL, Spry NA, Oliver T International study into the use of intermittent hormone therapy in the treatment of carcinoma of the prostate: a meta-analysis of 1446 patients.. vol.99, (5) 1056 - 1065.
10.1111/j.1464-410X.2007.06770.x
BJU Int2007
Donovan MJ, Hamann S, Clayton M, Teverovskiy M, Vengrenyuk Y, Khan F, Eggener SE, Reuter VE, Cooper C, Cordon-Cardo C, Cuzick J, Scardino PT Predicting disease specific survival at the time of diagnosis utilizing clinical variables integrated with quantitative immunofluorescence.. vol.177, (4) 590 - 590.JOURNAL OF UROLOGY2007
Cuzick J, Forbes JF, Sestak I, Cawthorn S, Hamed H, Holli K, Howell A, International Breast Cancer Intervention Study I Investigators Long-term results of tamoxifen prophylaxis for breast cancer--96-month follow-up of the randomized IBIS-I trial.. vol.99, (4) 272 - 282.
10.1093/jnci/djk049
J Natl Cancer Inst2007
Ronco G, Cuzick J, Segnan N, Brezzi S, Carozzi F, Folicaldi S, Dalla Palma P, Del Mistro A, Gillio-Tos A, Giubilato P, Naldoni C, Polla E, Iossa A, Zorzi M, Confortini M, Giorgi-Rossi P, NTCC working group HPV triage for low grade (L-SIL) cytology is appropriate for women over 35 in mass cervical cancer screening using liquid based cytology.. vol.43, (3) 476 - 480.
10.1016/j.ejca.2006.11.013
Eur J Cancer2007
Roychoudhuri R, Robinson D, Putcha V, Cuzick J, Darby S, Møller H Increased cardiovascular mortality more than fifteen years after radiotherapy for breast cancer: a population-based study.. vol.7, () 9.
10.1186/1471-2407-7-9
BMC Cancer2007
Terry G, Ho L, Londesborough P, Duggan C, Hanby A, Cuzick J The expression of FHIT, PCNA and EGFR in benign and malignant breast lesions.. vol.96, (1) 110 - 117.
10.1038/sj.bjc.6603512
Br J Cancer2007
Sestk I, Edwards R, Howell A, Cuzick J Comparison of side-effect profiles during active treatment versus follow-up in the International Breast Cancer Intervention Study I tamoxifen prevention trial. vol.9, (1) .
10.1186/bcr1723
BREAST CANCER RESEARCH2007
Cuzick J, Sasieni P, Myles J, Tyrer J Estimating the effect of treatment in a proportional hazards model in the presence of non-compliance and contamination. vol.69, () 565 - 588.
10.1111/j.1467-9868.2007.00600.x
J ROY STAT SOC B2007
Howell A, Clarke RB, Evans G, Bundred N, Cuzick J, Santen R, Allred C Estrogen deprivation for breast cancer prevention.. vol.174, () 151 - 167.Recent Results Cancer Res2007
Szarewski A, Cadman L, Mallett S, Austin J, Londesborough P, Waller J, Wardle J, Altman DG, Cuzick J Human papillomavirus testing by self-sampling: assessment of accuracy in an unsupervised clinical setting.. vol.14, (1) 34 - 42.
10.1258/096914107780154486
J Med Screen2007
Cuzick J, Cafferty FH, Edwards R, Møller H, Duffy SW Surrogate endpoints for cancer screening trials: general principles and an illustration using the UK Flexible Sigmoidoscopy Screening Trial.. vol.14, (4) 178 - 185.
10.1258/096914107782912059
J Med Screen2007
Chapman M, Howelli A, Cuzick J, Flyvbjerg A, Hopwood P, Jebb S, Parfitt G, Harvie M The effect of intermittent v. chronic energy restriction on weight loss in premenopausal women: preliminary results from a randomised pilot trial to reduce breast cancer risk. vol.66, () 99A - 99A.P NUTR SOC2007
Harvie M, Chapman M, Cuzick J, Flyvbjerg A, Hopwood P, Jebbs S, Parfitt G, Howell A The effect of intermittent versus chronic energy restriction on breast cancer risk biomarkers in premenopausal women: A randomized pilot trial. vol.137, (1) 283S - 283S.JOURNAL OF NUTRITION2007
Cella D, Fallowfield L, Barker P, Cuzick J, Locker G, Howell A, ATAC Trialistsa9 Group Quality of life of postmenopausal women in the ATAC ("Arimidex", tamoxifen, alone or in combination) trial after completion of 5 years' adjuvant treatment for early breast cancer.. vol.100, (3) 273 - 284.
10.1007/s10549-006-9260-6
Breast Cancer Res Treat2006
Cuzick J, Fisher G, Kattan MW, Berney D, Oliver T, Foster CS, Møller H, Reuter V, Fearn P, Eastham J, Scardino P, Transatlantic Prostate Group Long-term outcome among men with conservatively treated localised prostate cancer.. vol.95, (9) 1186 - 1194.
10.1038/sj.bjc.6603411
Br J Cancer2006
Cuzick J Chemoprevention of breast cancer.. vol.2, (6) 853 - 861.
10.2217/17455057.2.6.853
Womens Health (Lond)2006
Cox T, Cuzick J HPV DNA testing in cervical cancer screening: from evidence to policies.. vol.103, (1) 8 - 11.
10.1016/j.ygyno.2006.07.030
Gynecol Oncol2006
Cuzick J, Clavel C, Petry KU, Meijer CJLM, Hoyer H, Ratnam S, Szarewski A, Birembaut P, Kulasingam S, Sasieni P, Iftner T Overview of the European and North American studies on HPV testing in primary cervical cancer screening. vol.119, (5) 1095 - 1101.
10.1002/ijc.21955
INT J CANCER2006
Cuzick J, Mayrand MH, Ronco G, Snijders P, Wardle J Chapter 10: New dimensions in cervical cancer screening.. vol.24 Suppl 3, () S3/90 - S3/97.
10.1016/j.vaccine.2006.05.122
Vaccine2006
Franco EL, Cuzick J, Hildesheim A, de Sanjosé S Chapter 20: Issues in planning cervical cancer screening in the era of HPV vaccination.. vol.24 Suppl 3, () S3/171 - S3/177.
10.1016/j.vaccine.2006.05.061
Vaccine2006
Franco EL, Bosch FX, Cuzick J, Schiller JT, Garnett GP, Meheus A, Wright TC Chapter 29: Knowledge gaps and priorities for research on prevention of HPV infection and cervical cancer.. vol.24 Suppl 3, () S3/242 - S3/249.
10.1016/j.vaccine.2006.06.038
Vaccine2006
Wright TC, Bosch FX, Franco EL, Cuzick J, Schiller JT, Garnett GP, Meheus A Chapter 30: HPV vaccines and screening in the prevention of cervical cancer; conclusions from a 2006 workshop of international experts.. vol.24 Suppl 3, () S3/251 - S3/261.
10.1016/j.vaccine.2006.06.064
Vaccine2006
Sestak I, Kealy R, Edwards R, Forbes J, Cuzick J Influence of hormone replacement therapy on tamoxifen-induced vasomotor symptoms.. vol.24, (24) 3991 - 3996.
10.1200/JCO.2005.04.3745
J Clin Oncol2006
Arimidex, Tamoxifen, Alone or in Combination Trialists' Group , Buzdar A, Howell A, Cuzick J, Wale C, Distler W, Hoctin-Boes G, Houghton J, Locker GY, Nabholtz JM Comprehensive side-effect profile of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: long-term safety analysis of the ATAC trial.. vol.7, (8) 633 - 643.
10.1016/S1470-2045(06)70767-7
Lancet Oncol2006
Buzdar A, Chlebowski R, Cuzick J, Duffy S, Forbes J, Jonat W, Ravdin P Defining the role of aromatase inhibitors in the adjuvant endocrine treatment of early breast cancer.. vol.22, (8) 1575 - 1585.
10.1185/030079906X120940
Curr Med Res Opin2006
Eastell R, Hannon RA, Cuzick J, Dowsett M, Clack G, Adams JE, ATAC Trialists' group Effect of an aromatase inhibitor on bmd and bone turnover markers: 2-year results of the Anastrozole, Tamoxifen, Alone or in Combination (ATAC) trial (18233230).. vol.21, (8) 1215 - 1223.
10.1359/jbmr.060508
J Bone Miner Res2006
Buzdar AU, Guastalla J-P, Nabholtz J-M, Cuzick J, ATAC Trialists' Group Impact of chemotherapy regimens prior to endocrine therapy: Results from the ATAC (Anastrozole and Tamoxifen, Alone or in Combination) trial.. vol.107, (3) 472 - 480.
10.1002/cncr.22042
Cancer2006
Ronco G, Giorgi-Rossi P, Carozzi F, Dalla Palma P, Del Mistro A, De Marco L, De Lillo M, Naldoni C, Pierotti P, Rizzolo R, Segnan N, Schincaglia P, Zorzi M, Confortini M, Cuzick J, New Technologies for Cervical Cancer screening Working Group Human papillomavirus testing and liquid-based cytology in primary screening of women younger than 35 years: results at recruitment for a randomised controlled trial.. vol.7, (7) 547 - 555.
10.1016/S1470-2045(06)70731-8
Lancet Oncol2006
Ronco G, Segnan N, Giorgi-Rossi P, Zappa M, Casadei GP, Carozzi F, Dalla Palma P, Del Mistro A, Folicaldi S, Gillio-Tos A, Nardo G, Naldoni C, Schincaglia P, Zorzi M, Confortini M, Cuzick J, New Technologies for Cervical Cancer Working Group Human papillomavirus testing and liquid-based cytology: results at recruitment from the new technologies for cervical cancer randomized controlled trial.. vol.98, (11) 765 - 774.
10.1093/jnci/djj209
J Natl Cancer Inst2006
Cuzick J, Forbes JF, Howell A Re: Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study.. vol.98, (9) 643.
10.1093/jnci/djj167
J Natl Cancer Inst2006
Buzdar AU, Baum M, Cuzick J Letrozole or tamoxifen in early breast cancer.. vol.354, (14) 1528 - 1530.
10.1056/NEJMc060194
N Engl J Med2006
Dowsett M, Cuzick J, Wale C, Howell T, Houghton J, Baum M, Buzdar A Progesterone receptor and human epidermal growth factor receptor 2 status: An independent influence on the efficacy of endocrine therapy in breast cancer? Reply. vol.24, (9) 1482 - 1482.
10.1200/JCO.2005.05.1623
J CLIN ONCOL2006
Houssami N, Cuzick J, Dixon JM The prevention, detection, and management of breast cancer.. vol.184, (5) 230 - 234.Med J Aust2006
Cuzick J, Sasieni P, Howell A Should aromatase inhibitors be used as initial adjuvant treatment or sequenced after tamoxifen?. vol.94, (4) 460 - 464.
10.1038/sj.bjc.6602964
Br J Cancer2006
Buzdar AU, Cuzick J Anastrozole as an adjuvant endocrine treatment for postmenopausal patients with breast cancer: emerging data.. vol.12, (3 Pt 2) 1037s - 1048s.
10.1158/1078-0432.CCR-05-2458
Clin Cancer Res2006
Cuzick J Keynote comment: Chemoprevention of cancer--time to catch up with the cardiologists.. vol.7, (2) 98 - 99.
10.1016/S1470-2045(06)70547-2
Lancet Oncol2006
Howell A, Cuzick J Vascular effects of aromatase inhibitors: Data from clinical trials (vol 95, pg 143, 2005). vol.98, (2-3) 180 - 180.
10.1016/j.jsbmb.2005.11.003
J STEROID BIOCHEM2006
Cuzick J, Wale C, ATAC Trialists' Group A detailed analysis of the benefits of anastrozole over tamoxifen for venous thromboembolic events (VTEs) after 5 years' treatment.. vol.100, () S24 - S24.BREAST CANCER RESEARCH AND TREATMENT2006
Ronco G, Segnan N, Confortini M, Giorgi-Rossi P, Vettorazzi M, Naldoni C, Palma PD, Cuzick J A randomises trial on HPV testing for primary cervical screening: Data at recruitment.. vol.21, () 53 - 53.EUR J EPIDEMIOL2006
Cuzick J Bone versus breast density.. vol.8, (3) 104.
10.1186/bcr1407
Breast Cancer Res2006
Gao JN, Forbes JF, Warren RML, Cuzick J, Howell A, D'Este C, Warren-Forward H Change in marnmographic density after cessation of tamoxifen: results from international breast cancer intervention study I (IBIS I).. vol.100, () S56 - S56.BREAST CANCER RESEARCH AND TREATMENT2006
Sestak I, Forbes J, Roseann K, Edwards R, Howell A, Cuzick J Comparison of side-effect profiles during active treatment versus follow-up in the IBIS-1 tamoxifen prevention study.. vol.100, () S55 - S55.BREAST CANCER RESEARCH AND TREATMENT2006
Singh S, Richmond B, Howell A, Cuzick J Effect of anastrozole on cholesterol fractions in postmenopausal women with high risk of breast cancer: results from IBIS-II breast cancer prevention study.. vol.100, () S57 - S57.BREAST CANCER RESEARCH AND TREATMENT2006
Harvie M, Chapman M, Cuzick J, Flyvbjerg A, Hopwood P, Jebb S, Parfitt G, Howell A Effect of intermittent versus chronic energy restriction on breast cancer risk biomarkers in premenopausal women: A randomised pilot trial. vol.8, () S14 - S14.
10.1186/bcr1584
BREAST CANCER RESEARCH2006
Berney DM, Fisher G, Cuzick J, Scardino P, Kattan M, Reuter V, Foster CS Gleason score and survival in conservatively treated localised prostate cancer. vol.19, () 130A - 130A.MODERN PATHOLOGY2006
Cuzick J, IBIS Investigators Long term efficacy of tamoxifen for chemoprevention - results of the IBIS-I study.. vol.100, () S16 - S17.BREAST CANCER RESEARCH AND TREATMENT2006
Berney DM, Cuzick J, Scardino P, Fisher G, Kattan M, Foster CS, Reuter V Pitfalls in the diagnosis of prostate cancer. A review of 1861 cases. vol.86, () 130A - 130A.LABORATORY INVESTIGATION2006
Cuzick J, Warren R, Pinney L, Warwick J, Howell A The effect of anastrozole, tamoxifen or a combination of both drugs on mammographic breast density in post menopausal women with breast cancer.. vol.100, () S224 - S224.BREAST CANCER RESEARCH AND TREATMENT2006
Cuzick J, LHRH-Agonist Overview Group The impact of LHRH agonists on breast cancer recurrence and mortality: an overview of the randomized trials.. vol.100, () S10 - S10.BREAST CANCER RESEARCH AND TREATMENT2006
Singh S, Howell A, Cuzick J Vit D levels among patients with Arthralgia: results from IBIS-II breast cancer prevention study.. vol.100, () S61 - S61.BREAST CANCER RESEARCH AND TREATMENT2006
Abe O, Abe R, Enomoto K, Kikuchi K, Koyama H, Masuda H, Nomura Y, Sakai K, Sugimachi K, Tominaga T, Uchino J, Yoshida M, Haybittle JL, Davies C, Harvey VJ, Holdaway TM, Kay RG, Mason BH, Forbes JF, Wilcken N Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials. vol.366, (9503) 2087 - 2106.
10.1016/S0140-6736(05)67887-7
LANCET2005
Buzdar AU, Cuzick J Optimum use of aromatase inhibitors in the adjuvant treatment of early breast cancer.. vol.23, (33) 8544 - 8546.
10.1200/JCO.2005.03.7416
J Clin Oncol2005
Forbes JF, Cuzick J Systemic adjuvant therapies for early breast cancer: 15-year results for recurrence and survival.. vol.183, (9) 447 - 448.Med J Aust2005
Cuzick J Breast cancer prevention - Beyond tamoxifen.. vol.14, (11) 2804S - 2804S.CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION2005
Dowsett M, Cuzick J, Wale C, Howell T, Houghton J, Baum M Retrospective analysis of time to recurrence in the ATAC trial according to hormone receptor status: an hypothesis-generating study.. vol.23, (30) 7512 - 7517.
10.1200/JCO.2005.01.4829
J Clin Oncol2005
Cuzick J Can HPV testing challenge the PAP smear?. vol.3, (2) 9 - 9.EJC SUPPL2005
Goldhirsch A, Glick JH, Gelber RD, Coates AS, Thurlimann B, Senn H, Albain KS, Bergh J, Castiglione-Gertsch M, Coates AS, Costa A, Cuzick J, Davidson N, Forbes JF, Gelber RD, Goss P, Harris J, Glick JH, Goldhirsch A, Howell A Meeting highlights: International Expert Consensus on the Primary Therapy of Early Breast Cancer 2005. vol.16, (10) 1569 - 1583.
10.1093/annonc/mdi326
ANN ONCOL2005
Cuzick J The implications of delaying the start of aromatase inhibitor (AI) therapy. vol.3, (2) 109 - 110.EJC SUPPL2005
Bataille V, Boniol M, De Vries E, Severi G, Brandberg Y, Sasieni P, Cuzick J, Eggermont A, Ringborg U, Grivegnée A-R, Coebergh JW, Chignol MC, Doré J-F, Autier P A multicentre epidemiological study on sunbed use and cutaneous melanoma in Europe.. vol.41, (14) 2141 - 2149.
10.1016/j.ejca.2005.04.038
Eur J Cancer2005
Bataille V, Boniol M, De Vries E, Severi G, Brandberg Y, Sasieni P, Cuzick J, Eggermont A, Ringborg U, Grivegnee AR, Coebergh JW, Dore JF, Autier P Sunbed use and melanoma: a multi-centre case-control study of melanoma in Europe. vol.153, () 2 - 2.BRITISH JOURNAL OF DERMATOLOGY2005
Baum M, Cuzick J, Howell A, Buzdar A, Demicheli R, Greco M, Retsky M, Hrushesky B, ATAC Trialists' Grp An exploration of relapse data by hazard rate as a means of developing biological insights into the natural history and treatment of breast cancer: Data from the 'Arimidex', Tamoxifen, Alone or in Combination (ATAC) trial and the Milan Institute database.. vol.23, (16) 31S - 31S.JOURNAL OF CLINICAL ONCOLOGY2005
Kattan MW, Cuzick J, Scardino PT, Transatlantic Prostate Grp Natural history of prostate cancer in a large cohort of untreated patients in the United Kingdom.. vol.23, (16) 381S - 381S.JOURNAL OF CLINICAL ONCOLOGY2005
Cuzick J, Howell A Optimal timing of the use of an aromatase inhibitor in the adjuvant treatment of postmenopausal hormone receptor-positive breast cancer.. vol.23, (16) 43S - 43S.JOURNAL OF CLINICAL ONCOLOGY2005
Cuzick J, Duffy S, Tyrer J A breast cancer prediction model - Authors' reply. vol.24, (10) 1612 - 1612.
10.1002/sim.2014
STAT MED2005
Cuzick J Interaction of statisticians with DMCs.. vol.24, (10) 1609.
10.1002/sim.2027
Stat Med2005
Abe O, Abe R, Enomoto K, Kikuchi K, Koyama H, Masuda H, Nomura Y, Sakai K, Sugimachi K, Tominaga T, Uchino J, Yoshida M, Haybittle JL, Davies C, Harvey VJ, Holdaway TM, Kay RG, Mason BH, Forbes JF, Wilcken N Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. vol.365, (9472) 1687 - 1717.
10.1016/S0140-6736(05)66544-0
LANCET2005
Howell A, Cuzick J Vascular effects of aromatase inhibitors: Data from clinical trials. vol.95, (1-5) 143 - 149.
10.1016/j.jsbmb.2005.04.005
JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY2005
Cuzick J Forest plots and the interpretation of subgroups.. vol.365, (9467) 1308.
10.1016/S0140-6736(05)61026-4
Lancet2005
Cuzick J Anastrozole. vol.41, (4) 227 - 239.
10.1358/dot.2005.41.4.908563
DRUG TODAY2005
Cuzick J Radiotherapy for breast cancer. vol.97, (6) 406 - 407.
10.1093/jnci/dji086
J NATL CANCER I2005
Cuzick J Aromatase inhibitors for breast cancer prevention. vol.23, (8) 1636 - 1643.
10.1200/JCO.2005.11.027
J CLIN ONCOL2005
Tyrer J, Duffy SW, Cuzick J A breast cancer prediction model incorporating familial and personal risk factors (vol 23, pg 1111, 2004). vol.24, (1) 156 - 156.
10.1002/sim.1913
STAT MED2005
Cuzick J Chemoprevention: beyond tamoxifen. vol.7, () S9 - S9.
10.1186/bcr1219
BREAST CANCER RESEARCH2005
Cuzick J, Howell A, Forbes J Early stopping of clinical trials. vol.7, (5) 181 - 183.
10.1186/bcr1280
BREAST CANCER RES2005
Shaw GL, Cuzick J, Prapotnich D, Spry N, Tucker S, Zerbib M, Goldenberg SL, Malone S, Small E, Oliver T International study of the use of intermittent hormone therapy for cancer of the prostate (ISICAP). vol.16, () 294 - 294.ANNALS OF ONCOLOGY2005
Howell A, Cuzick J, Baum M, Buzdar A, Dowsett M, Forbes JF, Hoctin-Boes G, Houghton I, Locker GY, Tobias JS, ATAC Tralists' Grp Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer. vol.365, (9453) 60 - 62.
10.1016/S0140-6736(04)17666-6
LANCET2005
SASIENI P, Cuzick J Screening. vol., () 480 - 502.2005
CUZICK JM Testing Times (Book reviews on 'Should I be tested for Cancer?' by H Gilbert Welch). vol.6, () 12 - 13.Lancet Oncology2005
Sestak I, Kealy R, Edwards R, Cuzick J The influence of hormone replacement therapy (HRT) on tamoxifen induced vasomotor symptoms.. vol.94, () S11 - S12.BREAST CANCER RESEARCH AND TREATMENT2005
Terry G, Ho L, Londesborough P, Cross P, Lopes A, Monaghan J, Cuzick J The role of human papillomavirus type 16 and the fragile histidine triad gene in the outcome of cervical neoplastic lesions.. vol.91, (12) 2056 - 2062.
10.1038/sj.bjc.6602253
Br J Cancer2004
Fallowfield L, Cella D, Cuzick J, Francis S, Locker G, Howell A Quality of life of postmenopausal women in the Arimidex, Tamoxifen, Alone or in Combination (ATAC) Adjuvant Breast Cancer Trial.. vol.22, (21) 4261 - 4271.
10.1200/JCO.2004.08.029
J Clin Oncol2004
Locker GY, Sainsbury JR, Cuzick J, ATAC Trialists' Group Breast surgery in the 'Arimidex, Tamoxifen Alone or in Combination' (ATAC) trial: American women are more likely than women from the United Kingdom to undergo mastectomy.. vol.101, (4) 735 - 740.
10.1002/cncr.20435
Cancer2004
Sainsbury R, Locker G, Cuzick J, ATAC Trialists Group The use of adjuvant chemotherapy in the ATAC trial: Nationality correlates with the use of chemotherapy.. vol.22, (14_suppl) 597.J Clin Oncol2004
Atkin W, Rogers P, Cardwell C, Cook C, Cuzick J, Wardle J, Edwards R Wide variation in adenoma detection rates at screening flexible sigmoidoscopy.. vol.126, (5) 1247 - 1256.
10.1053/j.gastro.2004.01.023
Gastroenterology2004
Cuzick J, Warwick J, Pinney E, Warren RML, Duffy SW Tamoxifen and breast density in women at increased risk of breast cancer. vol.96, (8) 621 - 628.
10.1093/jnci/djh106
J NATL CANCER I2004
Tyrer J, Duffy SW, Cuzick J A breast cancer prediction model incorporating familial and personal risk factors.. vol.23, (7) 1111 - 1130.
10.1002/sim.1668
Stat Med2004
Cuzick J, Buzdar A, Baum M, Bianco R, Coleman R, Constenla M, Distler W, Dowsett M, Forbes J, Guastalla JP, Houghton J, Williams N, Howell A, Locker G, MacKey J, Sainsbury R, Tobias J Adjuvant use of anastrozole in breast cancer.. vol.22, (8) 1524 - 1526.
10.1200/JCO.2004.99.165
J Clin Oncol2004
Sasieni P, Adams J, Cuzick J Reply: The value of case-control audits of screening. vol.90, (5) 1109 - 1110.
10.1038/sj.bjc.6601599
BRIT J CANCER2004
Bataille V, Winnett A, Sasieni P, Bishop JAN, Cuzick J Exposure to the sun and sunbeds and the risk of cutaneous melanoma in the UK: a case-control study. vol.40, (3) 429 - 435.
10.1016/j.ejca.2003.09.030
EUR J CANCER2004
Fielder HM, Warwick J, Brook D, Gower-Thomas K, Cuzick J, Monypenny I, Duffy SW A case-control study to estimate the impact on breast cancer death of the breast screening programme in Wales.. vol.11, (4) 194 - 198.
10.1258/0969141042467304
J Med Screen2004
Cuzick J Chemoprevention of breast cancer. vol.58, (1) 71 - 71.
10.1016/S0753-3322(03)00041-6
BIOMED PHARMACOTHER2004
Cuzick J, DUFFY SW, Warren RML, Pinney E, Warwick J Effect of tamoxifen on women at increased risk of breast cancer.. vol.96, () 621 - 628.J Natl. Cancer Institute.2004
CUZICK JM, Hamed H, O'neill C Genetic and other factors related to tamoxifen-associated venous thromboembolic.. vol.3, () 405 - 406.The American Journal of Oncology Review.2004
CUZICK JM Screening for cervical cancer.. vol., () 261 - 299.
10.7326/0003-4819-156-8-201204170-00011
2004
Cuzick J, Szarewski A, Cubie H, Hulman G, Kitchener H, Luesley D, McGoogan E, Menon U, Terry G, Edwards R, Brooks C, Desai M, Gie C, Ho L, Jacobs I, Pickles C, Sasieni P Management of women who test positive for high-risk types of human papillomavirus: the HART study. vol.362, (9399) 1871 - 1876.
10.1016/S0140-6736(03)14955-0
LANCET2003
Cuzick J Epidemiology of breast cancer - selected highlights. vol.12, (6) 405 - 411.
10.1016/S0960-9776(03)00144-9
BREAST2003
Duffy S, Jackson TL, Lansdown M, Philips K, Wells M, Pollard S, Clack G, Cuzick J, Coibion M, Bianco AR The ATAC adjuvant breast cancer trial in postmenopausal women: baseline endometrial subprotocol data.. vol.110, (12) 1099 - 1106.
10.1111/j.1471-0528.2003.02120.x
BJOG2003
Cuzick J Treatment of DCIS--results from clinical trials.. vol.12, (4) 213 - 219.
10.1016/j.suronc.2003.09.001
Surg Oncol2003
Baum M, Buzdar A, Cuzick J, Forbes J, Houghton J, Howell A, Sahmoud T, ATAC (Arimidex, Tamoxifen Alone or in Combination) Trialists' Group Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer: results of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial efficacy and safety update analyses.. vol.98, (9) 1802 - 1810.
10.1002/cncr.11745
Cancer2003
Cuzick J, EDWARDS R, Marriott K, Duggan C Inherited and acquired risk factors for venous thromboembolic disease among women taking tamoxifen to prevent breast cancer. vol.21, () 3588 - 3593.
10.1200/JCO.2003.10.111
J Clin Oncol2003
Cuzick J, O'Neill C, Howell T, Forbes J Anastrozole for ductal carcinoma in situ. vol.362, (9386) 832 - 833.
10.1016/S0140-6736(03)14257-2
LANCET2003
Kaufmann M, Jonat W, Blamey R, Cuzick J, Namer M, Fogelman I, de Haes JC, Schumacher M, Sauerbrei W, Zoladex Early Breast Cancer Research Association (ZEBRA) Trialists' Group Survival analyses from the ZEBRA study. goserelin (Zoladex) versus CMF in premenopausal women with node-positive breast cancer.. vol.39, (12) 1711 - 1717.
10.1016/S0959-8049(03)00392-7
Eur J Cancer2003
Sasieni P, Cuzick J The UK breast-screening programme should start at age 47 years. vol.362, (9379) 246 - 247.
10.1016/S0140-6736(03)13922-0
LANCET2003
Houghton J, George WD, Cuzick J, Duggan C, Fentiman IS, Spittle M, UK Coordinating Committee on Cancer Research , Ductal Carcinoma in situ Working Party , DCIS trialists in the UK, Australia, and New Zealand Radiotherapy and tamoxifen in women with completely excised ductal carcinoma in situ of the breast in the UK, Australia, and New Zealand: randomised controlled trial.. vol.362, (9378) 95 - 102.
10.1016/S0140-6736(03)13859-7
Lancet2003
Sasieni P, Adams J, Cuzick J Benefit of cervical screening at different ages: evidence from the UK audit of screening histories. vol.89, (1) 88 - 93.
10.1038/sj.bjc.6600974
BRIT J CANCER2003
De Vries E, Boniol M, Severi G, Brandberg Y, Eggermont A, Ringborg U, Grivegnee A, Coebergh JW, Dore JF, Autier P, Cuzick J, Batailler B Sunbed use in melanoma cases and controls in Europe: a European Union multicentre case-control study. vol.149, () 87 - 88.BRITISH JOURNAL OF DERMATOLOGY2003
Warwick J, Pinney E, Warren RML, Duffy SW, Howell A, Wilson M, Cuzick J Breast density and breast cancer risk factors in a high-risk population. vol.12, (1) 10 - 16.
10.1016/S0960-9776(02)00212-6
BREAST2003
Cuzick J, Powles T, Veronesi U, Forbes J, Edwards R, Ashley S, Boyle P Overview of the main outcomes in breast-cancer prevention trials. vol.361, (9354) 296 - 300.
10.1016/S0140-6736(03)12342-2
LANCET2003
Cuzick J, Forbes J, Howell A, IBIS Investigators Tamoxifen for breast-cancer prevention - Reply. vol.361, (9352) 178 - 178.
10.1016/S0140-6736(03)12212-X
LANCET2003
Cuzick J Aromatase inhibitors in prevention - Data from the ATAC (arimidex, tamoxifen alone or in combination) trial and the design of IBIS-II (the second international breast cancer intervention study). vol.163, () 96 - 103.TUMOR PREVENTION AND GENETICS2003
CUZICK JM Breast Cancer Prevention Trials.. vol., () 48 - 52.2003
CUZICK JM, Baum M, Houghton J Chapter 6. Design and statistical considerations.. vol., () 37 - 44.2003
CUZICK JM Chemoprevention of Breast Cancer.. vol.2, () 319 - 321.The American Journal of Oncology Review2003
Sasieni P, CUZICK JM Epidemiology of gynaecological cancer.. vol., () 513 - 526.2003
CUZICK JM Human Papilloma Screening for lower genital tract neoplasia.. vol., () 108 - 113.2003
Ho L, Terry G, Londesborough P, Cuzick J, Lorenzato F, Singer A Human papillomavirus DNA detection in the management of women with twice mildly abnormal cytological smears. vol.69, (1) 118 - 121.
10.1002/jmv.10257
J MED VIROL2003
CUZICK JM, Veronesi U, Boyle P, Ashley S, Powles T, Forbes J, Edwards R Overview of the main outcomes in breast cancer prevention trials.. vol.58, (7) 463 - 465.
10.1097/01.OGX.0000074099.38382.13
Obstet Gynae Survey2003
Sauerbrei W, Schumacher M, Cuzick J, Jonat W, Kaufmann M Prognostic factors determine groups with different prognoses in pre- and perimenopausal women with estrogen receptor-positive, node-positive breast cancer treated with goserelin (Zoladex (R)) or CMF - results from the ZEBRA study.. vol.82, () S121 - S121.BREAST CANCER RESEARCH AND TREATMENT2003
Wardle J, Williamson S, Sutton S, Biran A, McCaffery K, Cuzick J, Atkin W Psychological impact of colorectal cancer screening. vol.22, (1) 54 - 59.
10.1037/0278-6133.22.1.54
HEALTH PSYCHOL2003
CUZICK JM Vaccination against cervical cancer - trial boost hopes [Editorial]. vol.8, () 5 - 6.Trends in Urology Gynaecology and Sexual Health2003
Jonat W, Kaufmann M, Sauerbrei W, Blamey R, Cuzick J, Namer M, Fogelman I, de Haes JC, de Matteis A, Stewart A, Eiermann W, Szakolczai I, Palmer M, Schumacher M, Geberth M, Lisboa B, Zoladex Early Breast Cancer Research Association Study Goserelin versus cyclophosphamide, methotrexate, and fluorouracil as adjuvant therapy in premenopausal patients with node-positive breast cancer: The Zoladex Early Breast Cancer Research Association Study.. vol.20, (24) 4628 - 4635.
10.1200/JCO.2002.05.042
J Clin Oncol2002
Locker G, Sainsbury R, Cuzick J, ATAC Trialists' Grp Breast surgery in the ATAC trial: women from the United States are more likely to have mastectomy.. vol.76, () S35 - S35.BREAST CANCER RESEARCH AND TREATMENT2002
Kaufmann M, Jonat W, Blarney R, Cuzick J, Fogelman I, De Haes J, Namer M, Sauerbrei W, Schumacher M Updated survival results from the Zebra trial.. vol.76, () S73 - S73.BREAST CANCER RESEARCH AND TREATMENT2002
Hamajima N, Hirose K, Tajima K, Rohan T, Calle EE, Heath CW, Coates RJ, Liff JM, Talamini R, Chantarakul N, Koetsawang S, Rachawat D, Morabia A, Schuman L, Stewart W, Szklo M, Bain C, Schofield F, Siskind V, Band P Alcohol, tobacco and breast cancer--collaborative reanalysis of individual data from 53 epidemiological studies, including 58,515 women with breast cancer and 95,067 women without the disease.. vol.87, (11) 1234 - 1245.
10.1038/sj.bjc.6600596
Br J Cancer2002
Ashton HA, Buxton MJ, Campbell HE, Day NE, Kim LG, Marteau TM, Scott RAP, Thompson SG, Barker P, Collin J, Morris G, Sutton G, Wilson NK, Bridgewater S, Druce PS, Hardy EJ, Lodge S, Pettifer M, Woronowski H, Dewbury K Multicentre aneurysm screening study (MASS): cost effectiveness analysis of screening for abdominal aortic aneurysms based on four year results from randomised controlled trial. vol.325, (7373) 1135 - 1138B.BRIT MED J2002
Cuzick J Prevention of breast cancer. vol.38, () S85 - S86.EUROPEAN JOURNAL OF CANCER2002
Cuzick J Rationale for a study testing aromatase inhibitors in prevention and DCIS. vol.38, () S81 - S81.EUROPEAN JOURNAL OF CANCER2002
Cuzick J Role of HPV testing in clinical practice.. vol.89, (2) 263 - 269.
10.1016/S0168-1702(02)00194-6
Virus Res2002
Eccles DM, Dowsett M, Howell A, Evans G, Chapman K, Eeles R, Mackay J, Fallowfield L, Cuzick J The raloxifene plus zoladex (RAZOR) trial for breast cancer risk reduction.. vol.11, (10) 1194S - 1194S.CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION2002
Cuzick J, Forbes J, Edwards R, Baum M, Cawthorn S, Coates A, Hamed A, Howell A, Powles T, IBIS investigators First results from the International Breast Cancer Intervention Study (IBIS-I): a randomised prevention trial.. vol.360, (9336) 817 - 824.
10.1016/S0140-6736(02)09962-2
Lancet2002
Eastell R, Hannon RA, Cuzick J, Clack G, Adams JE Effect of anastrozole on bone density and bone turnover: Results of the 'Arimidex' (anastrozole), tamoxifen, alone or in combination (ATAC) study.. vol.17, () S165 - S165.JOURNAL OF BONE AND MINERAL RESEARCH2002
Jass JR, Atkin WS, Cuzick J, Bussey HJR, Morson BC, Northover JMA, Todd IP The grading of rectal cancer: historical perspectives and a multivariate analysis of 447 cases.. vol.41, (3A) 59 - 81.
10.1046/j.1365-2559.2002.14861.x
Histopathology2002
Baum M, Budzar AU, Cuzick J, Forbes J, Houghton JH, Klijn JGM, Sahmoud T, ATAC Trialists' Group Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial.. vol.359, (9324) 2131 - 2139.
10.1016/S0140-6736(02)09088-8
Lancet2002
Cuzick J Breast cancer screening--time to move forward.. vol.11, (3) 209 - 210.
10.1054/brst.2002.0439
Breast2002
Atkin WS, Cook CF, Cuzick J, Edwards R, Northover JMA, Wardle J, UK Flexible Sigmoidoscopy Screenin Single flexible sigmoidoscopy screening to prevent colorectal cancer: baseline findings of a UK multicentre randomised trial. vol.359, (9314) 1291 - 1300.
10.1016/S0140-6736(02)08268-5
LANCET2002
Cuzick J Update on new studies in Europe. vol.38, () S44 - S44.
10.1016/S0959-8049(02)80107-1
EUR J CANCER2002
Scott DR, Hagmar B, Maddox P, Hjerpe A, Dillner J, Cuzick J, Sherman ME, Stoler MH, Kurman RJ, Kiviat NB, Manos MM, Schiffman M Use of human papillomavirus DNA testing to compare equivocal cervical cytologic interpretations in the United States, Scandinavia, and the United Kingdom.. vol.96, (1) 14 - 20.
10.1002/cncr.10317
Cancer2002
Terry G, Ho L, Londesborough P, Cuzick J Abnormal FHIT expression profiles in cervical intraepithelial neoplastic (CIN) lesions.. vol.86, (3) 376 - 381.
10.1038/sj.bjc.6600077
Br J Cancer2002
Sasieni PD, Adams J, Cuzick J Avoidance of premature death: a new definition for the proportion cured.. vol.7, (4) 165 - 171.J Cancer Epidemiol Prev2002
Sasieni P, Cuzick J Cervical cancer - Could HPV testing become the sole primary cervical screening test?. vol.9, (2) 49 - 51.
10.1136/jms.9.2.49
J MED SCREEN2002
Duffy SW, Cuzick J, Tabar L, Vitak B, Chen THH, Yen MF, Smith RA Correcting for non-compliance bias in case-control studies to evaluate cancer screening programmes. vol.51, () 235 - 243.
10.1111/1467-9876.00266
J ROY STAT SOC C-APP2002
Sasieni P, Cuzick J Could HPV testing become the sole primary cervical screening test?. vol.9, (2) 49 - 51.
10.1136/jms.9.2.49
J Med Screen2002
Cuzick J, International Breast Cancer Intervention Study A brief review of the International Breast Cancer Intervention Study (IBIS), the other current breast cancer prevention trials, and proposals for future trials.. vol.949, () 123 - 133.
10.1111/j.1749-6632.2001.tb04010.x
Ann N Y Acad Sci2001
Cuzick J, Sasieni P Natural history of cervical human papillomavirus.. vol.358, (9292) 1550 - 1551.
10.1016/S0140-6736(01)06602-8
Lancet2001
Cuzick J Time to consider HPV testing in cervical screening.. vol.12, (11) 1511 - 1514.
10.1023/A:1013117823929
Ann Oncol2001
Duffy SW, Cuzick J Let's talk about mammographic screening over again - response. vol.10, (5) 450 - 451.BREAST2001
Bosch FX, Muñoz N, de Sanjosé S, Franco EL, Lowy DR, Schiffman M, Franceschi S, Kjaer SK, Meijer CJ, Frazer IH, Cuzick J Re: Cervical carcinoma and human papillomavirus: on the road to preventing a major human cancer.. vol.93, (17) 1349 - 1350.
10.1093/jnci/93.17.1349
J Natl Cancer Inst2001
Terry G, Ho L, Londesborough P, Cuzick J, Mielzynska-Lohnas I, Lorincz A Detection of high-risk HPV types by the hybrid capture 2 test.. vol.65, (1) 155 - 162.
10.1002/jmv.2015.abs
J Med Virol2001
Dowsett M, Cuzick J, Howell A, Jackson I, ATAC Trialists' Group Pharmacokinetics of anastrozole and tamoxifen alone, and in combination, during adjuvant endocrine therapy for early breast cancer in postmenopausal women: a sub-protocol of the 'Arimidex and tamoxifen alone or in combination' (ATAC) trial.. vol.85, (3) 317 - 324.
10.1054/bjoc.2001.1925
Br J Cancer2001
Cuzick J, George WD, Houghton J, DCIS Working Party UKCCCR trial of tamoxifen and/or radiotherapy for DCIS. vol.85, () 2 - 2.BRIT J CANCER2001
Cuzick J Is hormone replacement therapy safe for breast cancer patients?. vol.93, (10) 733 - 734.
10.1093/jnci/93.10.733
J Natl Cancer Inst2001
Sasieni P, Cuzick J Routine audit is an ethical requirement of screening.. vol.322, (7295) 1179.
10.1136/bmj.322.7295.1179
BMJ2001
Cuzick J A strong law for weighted sums of I.I.D. random variables (vol 8, pg 625, 1995). vol.14, (2) 605 - 605.
10.1023/A:1011132202003
J THEOR PROBAB2001
Fallowfield L, Fleissig A, Edwards R, West A, Powles TJ, Howell A, Cuzick J Tamoxifen for the prevention of breast cancer: psychosocial impact on women participating in two randomized controlled trials.. vol.19, (7) 1885 - 1892.
10.1200/JCO.2001.19.7.1885
J Clin Oncol2001
Cuzick J Event-based analysis times for randomised clinical trials. vol.88, (1) 245 - 253.
10.1093/biomet/88.1.245
BIOMETRIKA2001
Szarewski A, Maddox P, Royston P, Jarvis M, Anderson M, Guillebaud J, Cuzick J The effect of stopping smoking on cervical Langerhans' cells and lymphocytes.. vol.108, (3) 295 - 303.
10.1016/S0306-5456(00)00074-7
BJOG2001
Atkin WS, Edwards R, Wardle J, Northover JM, Sutton S, Hart AR, Williams CB, Cuzick J Design of a multicentre randomised trial to evaluate flexible sigmoidoscopy in colorectal cancer screening.. vol.8, (3) 137 - 144.
10.1136/jms.8.3.137
J Med Screen2001
Mackay J, Rogers C, Fielder H, Blamey R, Macmillan D, Boggis C, Brown J, Pharoah PD, Moss S, Day NE, Myles J, Austoker J, Gray J, Cuzick J, Duffy SW Development of a protocol for evaluation of mammographic surveillance services in women under 50 with a family history of breast cancer.. vol.6, (5) 365 - 369.
10.1080/135952201753337086
J Epidemiol Biostat2001
Cuzick J HPV testing in cervical screening.. vol.10, (1) 33 - 36.
10.1002/pds.558
Pharmacoepidemiol Drug Saf2001
Cuzick J Future possibilities in the prevention of breast cancer - Breast cancer prevention trials. vol.2, (4) 258 - 263.
10.1186/bcr66
BREAST CANCER RES2000
Brentnall AR, Duffy SW, Cuzick J Breast-Cancer Tumor Size and Screening Effectiveness.. vol.376, (1) 94.
10.1056/NEJMc1614282#SA3
N Engl J Med
Huh WK, Joura EA, Giuliano AR, Iversen OE, De Andrade RP, Ault KA, Bartholomew D, Cestero RM, Fedrizzi EN, Hirschberg AL, Mayrand MH, Ruiz-Stenberg AM, Stapleton JT, Wiley DJ, Ferenczy A, Kurman R, Ronnett BM, Stoler MH, Cuzick J, Garland SM EFFICACY, IMMUNOGENICITY, AND SAFETY OF A NINE-VALENT HUMAN PAPILLOMAVIRUS VACCINE IN WOMEN AGED 16–26 YEARS: FINAL ANALYSES OF A RANDOMISED, DOUBLE-BLIND TRIAL. vol., () .
10.1016/S0140-6736(17)31821-4
Lancet
BRENTNALL AR, Sasieni P, Cuzick J Estimating efficacy in trials with selective crossover. vol., () .
10.1002/sim.7275
Statistics in Medicine
CUZICK JM, Smith S, De Censi A General Practitioner attitudes towards prescribing tamoxifen for the primary prevention of breast cancer. vol., () .
10.3399/bjgp17X689377
British Journal of General Practice
Bosch FX, Robles C, Díaz M, Arbyn M, Baussano I, Clavel C, Ronco G, Dillner J, Lehtinen M, Petry K-U, Poljak M, Kjaer SK, Meijer CJLM, Garland SM, Salmerón J, Castellsagué X, Bruni L, de Sanjosé S, Cuzick J HPV-FASTER: broadening the scope for prevention of HPV-related cancer.. vol.13, (2) 119 - 132.
10.1038/nrclinonc.2015.146
Nat Rev Clin Oncol
Stankiewicz E, Xueying M, Mangham DC, Xu L, Yeste-Velasco M, Fisher G, North B, Chaplin T, Young B, Wang Y, Bansal JK, Kudahetti S, Spencer L, Foster CS, Moller H, Scardino P, Oliver RT, Shamash O, CUZICK JM, Cooper CS Identification of FBXL4 as a Metastasis Associated Gene in Prostate Cancer. vol., () .
10.1038/s41598-017-05209-z
Scientific Reports
Massat NJ, Dibden A, Parmar D, Cuzick J, Sasieni PD, Duffy SW Impact of Screening on Breast Cancer Mortality-Response.. vol.25, (5) 873.
10.1158/1055-9965.EPI-16-0170
Cancer Epidemiol Biomarkers Prev
CUZICK JM Impact of baseline covariates on the immunogenicity of the 9 valent HPV vaccine- A combined analysis of five phase III clinical trials. vol.3, () 105 - 115.
10.1016/j.pvr.2017.03.002
Papillomavirus research
Cuschieri K, Geraets D, Cuzick J, Cadman L, Moore C, Vanden Broeck D, Padalko E, Quint W, Arbyn M Performance of a cartridge based assay for the detection of clinically significant HPV infection – lessons from VALGENT (Validation of HPV Genotyping Tests). vol., () JCM.00897-16 - JCM.00897-16.
10.1128/JCM.00897-16
Journal of Clinical Microbiology
Cuzick J, Thorat MA Preventing invasive breast cancer using endocrine therapy. vol.Volume 32, Supplemen, () S7 - S8.
10.1016/S0960-9776(17)30071-1
The Breast
BRENTNALL AR, Cuzick J, Byers H, Segal C, Reuter C, Detre S, Sestak I, Howell A, Powles TJ, Newman WG, Dowsett M Relationship of ZNF423 and CTSO with breast cancer risk in two randomized tamoxifen-prevention trials. vol., () .
10.1007/s10549-016-3885-x
Breast Cancer Research and Treatment
Vasiljevic N, Carter P, Reuter C, Warman R, Brentnall A, Carton J, CUZICK JM, Lorincz A Role of quantitative p16INK4A mRNA assay and digital reading of p16INK4A immunostained sections in diagnosis of cervical intraepithelial neoplasia. vol., () .
10.1002/ijc.30783
International Journal of Cancer
RING AE, SESTAK I, BAUM M, HOWELL A, BUZDAR A, DOWSETT M, FORBES JF, CUZICK J The Influences of Co-Morbidities and Age on Risk of Death without Recurrence: A Retrospective Analysis of the ATAC Trial. vol., () .
10.1158/0008-5472.SABCS10-P5-13-03
BRENTNALL AR, Cuzick J Use of the concordance index for predictors of censored survival data. vol., () .
10.1177/0962280216680245
Statistical Methods in Medical Research
Return to top